Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8847766 | OTSUKA | Pharma-informatics system |
Mar, 2030
(5 years from now) | |
US8545402 | OTSUKA | Highly reliable ingestible event markers and methods for using the same |
Apr, 2030
(5 years from now) | |
US8114021 | OTSUKA | Body-associated receiver and method |
Jun, 2030
(5 years from now) | |
US11464423 | OTSUKA | In-body power source having high surface area electrode |
Sep, 2030
(5 years from now) | |
US9941931 | OTSUKA | System for supply chain management |
Nov, 2030
(5 years from now) | |
US8961412 | OTSUKA | In-body device with virtual dipole signal amplification |
Nov, 2030
(5 years from now) | |
US8258962 | OTSUKA | Multi-mode communication ingestible event markers and systems, and methods of using the same |
Nov, 2030
(5 years from now) | |
US8547248 | OTSUKA | Implantable zero-wire communications system |
Dec, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-150) | Dec 05, 2017 |
New Indication(I-746) | Jul 27, 2020 |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 13 November, 2017
Treatment: Method of using a tablet embedded with a sensor that communicates information via a signal through the body of a patient to a receiver
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8741959 | FRESENIUS KABI USA | Paracetamol for parenteral administration |
Apr, 2030
(5 years from now) |
Drugs and Companies using ACETAMINOPHEN ingredient
Market Authorisation Date: 28 October, 2015
Treatment: NA
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9962376 | JOHNSON JOHNSON VISN | Methods and ophthalmic devices used in the treatment of ocular allergies |
Jun, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Feb 25, 2025 |
Drugs and Companies using KETOTIFEN FUMARATE ingredient
Market Authorisation Date: 25 February, 2022
Treatment: NA
Dosage: DRUG-ELUTING CONTACT LENS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8915888 | SANOFI-AVENTIS US | Dosing and drive mechanism for drug delivery device |
Jun, 2030
(5 years from now) | |
US9981013 | SANOFI-AVENTIS US | Use of AVE0010 for the treatment of diabetes mellitus type 2 |
Aug, 2030
(5 years from now) | |
US9707176 | SANOFI-AVENTIS US | Pharmaceutical composition comprising a GLP-1 agonist and methionine |
Nov, 2030
(5 years from now) | |
US10028910 | SANOFI-AVENTIS US | Pharmaceutical composition comprising a GLP-1-agonist and methionine |
Nov, 2030
(5 years from now) | |
US9308329 | SANOFI-AVENTIS US | Medication delivery device and method for operating a medication delivery device |
Dec, 2030
(5 years from now) | |
US8475414 | SANOFI-AVENTIS US | Medication delivery device and method for operating a medication delivery device |
Dec, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jul 27, 2021 |
Drugs and Companies using LIXISENATIDE ingredient
NCE-1 date: 27 July, 2020
Market Authorisation Date: 27 July, 2016
Treatment: Improvement in glycemic control in type 2 diabetes mellitus patients by use of a pen injector; Improvement of glycemic control in type 2 diabetes patients by administering a starting dose of 10 mcg fo...
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9511198 | MANNKIND | Dry powder inhaler and system for drug delivery |
Feb, 2030
(5 years from now) | |
US8485180 | MANNKIND | Dry powder drug delivery system |
Mar, 2030
(5 years from now) | |
US8778403 | MANNKIND | Diketopiperazine microparticles with defined specific surface areas |
Jun, 2030
(5 years from now) | |
US8551528 | MANNKIND | Diketopiperazine microparticles with defined specific surface areas |
Jun, 2030
(5 years from now) | |
US8734845 | MANNKIND | Diketopiperazine microparticles with defined specific surface areas |
Jun, 2030
(5 years from now) | |
US10201672 | MANNKIND | Dry powder inhaler and system for drug delivery |
Aug, 2030
(5 years from now) | |
US10500159 | MANNKIND | Apparatus and method for cryogranulating a pharmaceutical composition |
Nov, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Jun 27, 2017 |
Drugs and Companies using INSULIN RECOMBINANT HUMAN ingredient
Market Authorisation Date: 27 June, 2014
Treatment: Method of aerosolizing/deagglomerating an insulin dry powder for use in treating diabetes mellitus via oral inhalation using an inhaler with a cartridge containing the insulin dry powder.; Administrat...
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9415009 | ASTRAZENECA | Compositions, methods and systems for respiratory delivery of two or more active agents |
May, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Jan 10, 2026 |
Drugs and Companies using ALBUTEROL SULFATE; BUDESONIDE ingredient
Market Authorisation Date: 10 January, 2023
Treatment: As-needed treatment or prevention of bronchoconstriction and reduction of the risk of exacerbations in patients with asthma 18 years of age and older
Dosage: AEROSOL, METERED
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US12042494 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Nov, 2030
(5 years from now) | |
US8623826 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Nov, 2030
(5 years from now) | |
US8951969 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Nov, 2030
(5 years from now) | |
US11559523 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Nov, 2030
(5 years from now) | |
US9186357 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Nov, 2030
(5 years from now) | |
US9943515 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Nov, 2030
(5 years from now) | |
US10828297 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Dec, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Apr 19, 2023 |
Drugs and Companies using NETUPITANT; PALONOSETRON HYDROCHLORIDE ingredient
NCE-1 date: 10 October, 2018
Market Authorisation Date: 10 October, 2014
Treatment: Method of treating emesis; Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy...
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9186357 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Nov, 2030
(5 years from now) | |
US10828297 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Dec, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Apr 19, 2023 |
NCE-1 date: 19 April, 2022
Market Authorisation Date: 19 April, 2018
Treatment: Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy
Dosage: POWDER; SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9440922 | HOFFMANN-LA ROCHE | Tetracyclic compound |
Jun, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-756) | Nov 06, 2020 |
New Chemical Entity Exclusivity(NCE) | Dec 11, 2020 |
Orphan Drug Exclusivity(ODE-105) | Dec 11, 2022 |
Orphan Drug Exclusivity(ODE) | Nov 06, 2024 |
Orphan Drug Exclusivity(ODE-159) | Nov 06, 2024 |
New Indication(I-947) | Apr 18, 2027 |
Orphan Drug Exclusivity(ODE-477) | Apr 18, 2031 |
Drugs and Companies using ALECTINIB HYDROCHLORIDE ingredient
NCE-1 date: 12 December, 2019
Market Authorisation Date: 11 December, 2015
Treatment: NA
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US10287586 | SAREPTA THERAPS INC | Antisense molecules and methods for treating pathologies |
Nov, 2030
(5 years from now) | |
US9228187 | SAREPTA THERAPS INC | Antisense molecules and methods for treating pathologies |
Nov, 2030
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9758783 | SAREPTA THERAPS INC | Antisense molecules and methods for treating pathologies |
Nov, 2030
(5 years from now) | |
US10781450 | SAREPTA THERAPS INC | Antisense molecules and methods for treating pathologies |
Nov, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Feb 25, 2026 |
Orphan Drug Exclusivity(ODE-347) | Feb 25, 2028 |
Drugs and Companies using CASIMERSEN ingredient
NCE-1 date: 25 February, 2025
Market Authorisation Date: 25 February, 2021
Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients who have a mutation of the dmd gene that is amenable to exon 45 skipping by restoring an mrna reading frame to induce dystrophin protein prod...
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10213512 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(5 years from now) | |
US10265404 | JOURNEY | Compositions, gels and foams with rheology modulators and uses thereof |
Oct, 2030
(5 years from now) | |
US8945516 | JOURNEY | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
Oct, 2030
(5 years from now) | |
US10086080 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(5 years from now) | |
US10517882 | JOURNEY | Method for healing of an infected acne lesion without scarring |
Oct, 2030
(5 years from now) | |
US8992896 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(5 years from now) | |
US9675700 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(5 years from now) | |
US10821187 | JOURNEY | Compositions, gels and foams with rheology modulators and uses thereof |
Oct, 2030
(5 years from now) | |
US8865139 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(5 years from now) | |
US10137200 | JOURNEY | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
Oct, 2030
(5 years from now) |
Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient
Market Authorisation Date: 18 October, 2019
Treatment: Treatment of non-nodular acne vulgaris
Dosage: AEROSOL, FOAM
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11253478 | BAUDAX | Reduction of flake-like aggregation in nanoparticulate active agent compositions |
May, 2030
(5 years from now) | |
US9974746 | BAUDAX | Reduction of flake-like aggregation in nanoparticulate active agent compositions |
May, 2030
(5 years from now) | |
US10709713 | BAUDAX | Nanoparticulate meloxicam formulations |
May, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Feb 20, 2023 |
Drugs and Companies using MELOXICAM ingredient
Market Authorisation Date: 20 February, 2020
Treatment: Management of moderate-to-severe pain by injection; Management of moderate-to-severe pain by intravenous injection
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8534281 | GLAXOSMITHKLINE | Manifold for use in medicament dispenser |
Mar, 2030
(5 years from now) | |
US8534281 (Pediatric) | GLAXOSMITHKLINE | Manifold for use in medicament dispenser |
Sep, 2030
(5 years from now) | |
US8746242 | GLAXOSMITHKLINE | Medicament dispenser |
Oct, 2030
(5 years from now) | |
US11090294 | GLAXOSMITHKLINE | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist |
Nov, 2030
(5 years from now) | |
US9750726 | GLAXOSMITHKLINE | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist |
Nov, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Dec 18, 2016 |
New Chemical Entity Exclusivity(NCE) | Dec 18, 2018 |
M(M-245) | Jun 09, 2022 |
Drugs and Companies using UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient
NCE-1 date: 18 December, 2017
Market Authorisation Date: 18 December, 2013
Treatment: Maintenance treatment of patients with chronic obstructive pulmonary disease (copd)
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9549923 | ZEVRA THERAP | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and uses thereof |
Jul, 2030
(5 years from now) | |
US9132125 | ZEVRA THERAP | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof |
Jul, 2030
(5 years from now) | |
US8748413 | ZEVRA THERAP | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof |
Jul, 2030
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8828978 | ZEVRA THERAP | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof |
Jul, 2030
(5 years from now) |
Drugs and Companies using ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 04 January, 2019
Treatment: Management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8865688 | SALIX | Compositions and methods for treatment of bowel diseases with granulated mesalamine |
May, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Oct 31, 2011 |
Drugs and Companies using MESALAMINE ingredient
Market Authorisation Date: 31 October, 2008
Treatment: For the maintenance of remission of ulcerative colitis
Dosage: CAPSULE, EXTENDED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8372431 | SUMITOMO PHARMA AM | Pharmaceutical composition comprising licarbazepine acetate |
Apr, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosing Schedule(D-150) | Aug 27, 2018 |
New Indication(I-715) | Aug 27, 2018 |
New Chemical Entity Exclusivity(NCE) | Nov 08, 2018 |
Drugs and Companies using ESLICARBAZEPINE ACETATE ingredient
NCE-1 date: 08 November, 2017
Market Authorisation Date: 08 November, 2013
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US10112903 | ALKERMES INC | Heterocyclic compounds for the treatment of neurological and psychological disorders |
Jun, 2030
(5 years from now) | |
US8431576 | ALKERMES INC | Heterocyclic compounds for the treatment of neurological and psychological disorders |
Oct, 2030
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8796276 | ALKERMES INC | Heterocyclic compounds for the treatment of neurological and psychological disorders |
Jun, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Oct 05, 2020 |
Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient
NCE-1 date: 06 October, 2019
Market Authorisation Date: 05 October, 2015
Treatment: Treatment of schizophrenia
Dosage: SUSPENSION, EXTENDED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US10112903 | ALKERMES INC | Heterocyclic compounds for the treatment of neurological and psychological disorders |
Jun, 2030
(5 years from now) | |
US8431576 | ALKERMES INC | Heterocyclic compounds for the treatment of neurological and psychological disorders |
Oct, 2030
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8796276 | ALKERMES INC | Heterocyclic compounds for the treatment of neurological and psychological disorders |
Jun, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Oct 05, 2020 |
Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient
NCE-1 date: 06 October, 2019
Market Authorisation Date: 29 June, 2018
Treatment: Treatment of schizophrenia
Dosage: SUSPENSION, EXTENDED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8714149 | TEVA PHARM | Airflow adaptor for a breath-actuated dry powder inhaler |
Nov, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population(NPP) | Jul 09, 2024 |
Pediatric Exclusivity(PED) | Jan 09, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 08 April, 2022
Treatment: NA
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8534281 | GLAXOSMITHKLINE | Manifold for use in medicament dispenser |
Mar, 2030
(5 years from now) | |
US8534281 (Pediatric) | GLAXOSMITHKLINE | Manifold for use in medicament dispenser |
Sep, 2030
(5 years from now) | |
US8746242 | GLAXOSMITHKLINE | Medicament dispenser |
Oct, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Aug 20, 2017 |
New Patient Population(NPP) | May 17, 2021 |
New Strength(NS) | May 17, 2021 |
M(M-290) | Mar 01, 2026 |
Drugs and Companies using FLUTICASONE FUROATE ingredient
Market Authorisation Date: 17 May, 2018
Treatment: NA
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8474447 | BOEHRINGER INGELHEIM | Inhaler device |
Jan, 2030
(4 years from now) |
Drugs and Companies using IPRATROPIUM BROMIDE ingredient
Market Authorisation Date: 27 November, 2004
Treatment: NA
Dosage: AEROSOL, METERED
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8802735 | SANOFI AVENTIS US | (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
Sep, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Sep 12, 2017 |
M(M-61) | Apr 30, 2024 |
Pediatric Exclusivity(PED) | Oct 30, 2024 |
Drugs and Companies using TERIFLUNOMIDE ingredient
NCE-1 date: 31 October, 2023
Market Authorisation Date: 12 September, 2012
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9387191 | KERYX BIOPHARMS | Ferric citrate dosage forms |
Jul, 2030
(5 years from now) | |
US10300039 | KERYX BIOPHARMS | Ferric citrate dosage forms |
Jul, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-790) | Nov 06, 2020 |
Drugs and Companies using FERRIC CITRATE ingredient
Market Authorisation Date: 05 September, 2014
Treatment: Control of serum phosphorus levels
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8835455 | ABBVIE | Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt |
Oct, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-738) | Jun 22, 2019 |
New Chemical Entity Exclusivity(NCE) | Feb 25, 2020 |
Generating Antibiotic Incentives Now(GAIN) | Feb 25, 2025 |
New Patient Population(NPP) | Dec 20, 2025 |
Drugs and Companies using AVIBACTAM SODIUM; CEFTAZIDIME ingredient
NCE-1 date: 26 February, 2024
Market Authorisation Date: 25 February, 2015
Treatment: NA
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8604020 | BAUSCH AND LOMB | Fluoroquinolone carboxylic acid molecular crystals |
Mar, 2030
(5 years from now) | |
US8415342 | BAUSCH AND LOMB | Besifloxacin ophthalmic composition for the treatment or control of infection |
Nov, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | May 28, 2014 |
Drugs and Companies using BESIFLOXACIN HYDROCHLORIDE ingredient
NCE-1 date: 28 May, 2013
Market Authorisation Date: 28 May, 2009
Treatment: Method of treating ocular bacterial infections
Dosage: SUSPENSION/DROPS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9415009 | ASTRAZENECA | Compositions, methods and systems for respiratory delivery of two or more active agents |
May, 2030
(5 years from now) | |
US10716753 | ASTRAZENECA | Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems |
May, 2030
(5 years from now) | |
US8324266 | ASTRAZENECA | Compositions, methods and systems for respiratory delivery of two or more active agents |
May, 2030
(5 years from now) | |
US8703806 | ASTRAZENECA | Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents |
May, 2030
(5 years from now) | |
US8808713 | ASTRAZENECA | Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems |
May, 2030
(5 years from now) | |
US9463161 | ASTRAZENECA | Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems |
May, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Apr 25, 2019 |
Drugs and Companies using FORMOTEROL FUMARATE; GLYCOPYRROLATE ingredient
Market Authorisation Date: 25 April, 2016
Treatment: Use for the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)
Dosage: AEROSOL, METERED
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8987463 | PORTOLA PHARMS INC | Methods of synthesizing factor Xa inhibitors |
Dec, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jun 23, 2022 |
Drugs and Companies using BETRIXABAN ingredient
NCE-1 date: 23 June, 2021
Market Authorisation Date: 23 June, 2017
Treatment: NA
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8617597 | BAYER HLTHCARE | Pharmaceutical composition containing a tetrahydrofolic acid |
Feb, 2030
(4 years from now) | |
US11617751 | BAYER HLTHCARE | Pharmaceutical composition containing a tetrahydrofolic acid |
Jul, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Combination(NC) | Sep 24, 2013 |
New Product(NP) | Sep 24, 2013 |
Drugs and Companies using DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM ingredient
Market Authorisation Date: 24 September, 2010
Treatment: Treatment of mood changes and/or anxiety as symptoms of premenstrual dysphoric disorder (pmdd) in women who choose to use an oral contraceptive as their method of contraception
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8541575 | ARRAY BIOPHARMA INC | 3,4-diarylpyrazoles as protein kinase inhibitors |
Feb, 2030
(5 years from now) | |
USRE49556 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Feb, 2030
(5 years from now) | |
US9593099 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(5 years from now) | |
US8501758 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9593100 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(5 years from now) | |
US10005761 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(5 years from now) | |
US9850229 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(5 years from now) | |
US9850230 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-826) | Apr 08, 2023 |
New Chemical Entity Exclusivity(NCE) | Jun 27, 2023 |
Orphan Drug Exclusivity(ODE-194) | Jun 27, 2025 |
New Indication(I-928) | Oct 11, 2026 |
Orphan Drug Exclusivity(ODE-445) | Oct 11, 2030 |
Drugs and Companies using ENCORAFENIB ingredient
NCE-1 date: 27 June, 2022
Market Authorisation Date: 27 June, 2018
Treatment: Braftovi is a kinase inhibitor indicated in combination with binimetinib, for the treatment of patients with metastatic non small cell lung cancer with a braf v600e mutation, as detected by an fda-app...
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8534281 | GLAXO GRP LTD | Manifold for use in medicament dispenser |
Mar, 2030
(5 years from now) | |
US8534281 (Pediatric) | GLAXO GRP LTD | Manifold for use in medicament dispenser |
Sep, 2030
(5 years from now) | |
US8746242 | GLAXO GRP LTD | Medicament dispenser |
Oct, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Apr 30, 2018 |
New Indication(I-708) | Apr 30, 2018 |
New Chemical Entity Exclusivity(NCE) | May 10, 2018 |
M(M-202) | May 15, 2020 |
New Patient Population(NPP) | May 13, 2026 |
New Strength(NS) | May 13, 2026 |
Pediatric Exclusivity(PED) | Nov 13, 2026 |
Drugs and Companies using FLUTICASONE FUROATE; VILANTEROL TRIFENATATE ingredient
NCE-1 date: 13 November, 2025
Market Authorisation Date: 12 May, 2023
Treatment: NA
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8188085 | SCYNEXIS | Antifungal agents |
Aug, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-903) | Nov 30, 2025 |
New Chemical Entity Exclusivity(NCE) | Jun 01, 2026 |
Generating Antibiotic Incentives Now(GAIN) | Jun 01, 2031 |
Drugs and Companies using IBREXAFUNGERP CITRATE ingredient
NCE-1 date: 01 June, 2030
Market Authorisation Date: 01 June, 2021
Treatment: Treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (vvc)
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10716753 | ASTRAZENECA AB | Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems |
May, 2030
(5 years from now) | |
US9415009 | ASTRAZENECA AB | Compositions, methods and systems for respiratory delivery of two or more active agents |
May, 2030
(5 years from now) | |
US8324266 | ASTRAZENECA AB | Compositions, methods and systems for respiratory delivery of two or more active agents |
May, 2030
(5 years from now) | |
US8808713 | ASTRAZENECA AB | Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems |
May, 2030
(5 years from now) | |
US8703806 | ASTRAZENECA AB | Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents |
May, 2030
(5 years from now) | |
US9463161 | ASTRAZENECA AB | Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems |
May, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Combination(NC) | Jul 23, 2023 |
Drugs and Companies using BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE ingredient
Market Authorisation Date: 23 July, 2020
Treatment: Use for the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)
Dosage: AEROSOL, METERED
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8425934 | ASTRAZENECA | Pharmaceutical compositions |
Apr, 2030
(5 years from now) | |
US8425934 (Pediatric) | ASTRAZENECA | Pharmaceutical compositions |
Oct, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jul 20, 2016 |
New Indication(I-714) | Sep 03, 2018 |
New Strength(NS) | Sep 03, 2018 |
New Indication(I-851) | May 28, 2023 |
New Indication(I-848) | Nov 05, 2023 |
M(M-283) | May 09, 2025 |
Pediatric Exclusivity(PED) | Nov 09, 2025 |
Drugs and Companies using TICAGRELOR ingredient
NCE-1 date: 09 November, 2024
Market Authorisation Date: 03 September, 2015
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10729653 | UCB INC | Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives |
Apr, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | May 12, 2021 |
New Patient Population(NPP) | Aug 27, 2024 |
Drugs and Companies using BRIVARACETAM ingredient
NCE-1 date: 12 May, 2020
Market Authorisation Date: 12 May, 2016
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8685934 | ASTRAZENECA AB | Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof |
May, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Jan 27, 2015 |
M(M-162) | Sep 24, 2018 |
M(M-212) | Oct 20, 2020 |
M(M-224) | Apr 02, 2021 |
M(M-240) | Feb 15, 2022 |
New Patient Population(NPP) | Jul 22, 2024 |
Pediatric Exclusivity(PED) | Jan 22, 2025 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 27 January, 2012
Treatment: Treatment of type 2 diabetes mellitus in a patient, wherein glycemic control (hba1c < 7.0%) is not achievable using one or more of insulin, metformin, pioglitazone, or rosiglitazone
Dosage: FOR SUSPENSION, EXTENDED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8895033 | ASTRAZENECA AB | Sustained release formulations using non-aqueous carriers |
Oct, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Oct 20, 2020 |
M(M-240) | Feb 15, 2022 |
New Patient Population(NPP) | Jul 22, 2024 |
Pediatric Exclusivity(PED) | Jan 22, 2025 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 20 October, 2017
Treatment: As an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiab...
Dosage: SUSPENSION, EXTENDED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8998876 | ASTRAZENECA AB | Ampoule comprising an ampoule holder |
Jan, 2030
(4 years from now) | |
US8721615 | ASTRAZENECA AB | Ampoule comprising an ampoule holder |
Jan, 2030
(4 years from now) | |
US8685934 | ASTRAZENECA AB | Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof |
May, 2030
(5 years from now) | |
US8998876 (Pediatric) | ASTRAZENECA AB | Ampoule comprising an ampoule holder |
Jul, 2030
(5 years from now) | |
US8721615 (Pediatric) | ASTRAZENECA AB | Ampoule comprising an ampoule holder |
Jul, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-224) | Apr 02, 2021 |
M(M-240) | Feb 15, 2022 |
New Patient Population(NPP) | Jul 22, 2024 |
Pediatric Exclusivity(PED) | Jan 22, 2025 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 27 January, 2012
Treatment: Treatment of type 2 diabetes mellitus in a patient, wherein glycemic control (hba1c < 7.0%) is not achievable using one or more of insulin, metformin, pioglitazone, or rosiglitazone
Dosage: FOR SUSPENSION, EXTENDED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US11091439 | EXELIXIS INC | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer |
Jan, 2030
(4 years from now) | |
US8877776 | EXELIXIS INC | (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
Oct, 2030
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11098015 | EXELIXIS INC | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer |
Jan, 2030
(4 years from now) | |
US11091440 | EXELIXIS INC | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer |
Jan, 2030
(4 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Nov 29, 2017 |
New Product(NP) | Apr 25, 2019 |
New Indication(I-760) | Dec 19, 2020 |
New Indication(I-792) | Jan 14, 2022 |
New Indication(I-854) | Jan 22, 2024 |
New Indication(I-873) | Sep 17, 2024 |
Orphan Drug Exclusivity(ODE-227) | Jan 14, 2026 |
Orphan Drug Exclusivity(ODE-375) | Sep 17, 2028 |
Drugs and Companies using CABOZANTINIB S-MALATE ingredient
NCE-1 date: 29 November, 2016
Market Authorisation Date: 25 April, 2016
Treatment: Treatment of differentiated thyroid cancer that has progressed following prior vegfr-targeted therapy
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9012508 | CUMBERLAND PHARMS | Administration of intravenous ibuprofen |
Sep, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Jun 11, 2012 |
New Dosing Schedule(D-152) | Nov 20, 2018 |
M(M-128) | Nov 19, 2024 |
New Patient Population(NPP) | May 11, 2026 |
Drugs and Companies using IBUPROFEN ingredient
Market Authorisation Date: 11 June, 2009
Treatment: Management of mild to moderate pain, management of moderate to severe pain as an adjunct to opioid analgesics, reduction in fever through anti-inflammatory, analgesic, and antipyretic activity
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US11458119 | GENZYME CORP | Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase |
Nov, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Aug 19, 2019 |
Orphan Drug Exclusivity(ODE) | Aug 19, 2021 |
Orphan Drug Exclusivity(ODE-73) | Aug 19, 2021 |
Drugs and Companies using ELIGLUSTAT TARTRATE ingredient
NCE-1 date: 19 August, 2018
Market Authorisation Date: 19 August, 2014
Treatment: NA
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8933097 | CHATTEM SANOFI | Fexofenadine suspension formulation |
Aug, 2030
(5 years from now) |
Drugs and Companies using FEXOFENADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 24 January, 2011
Treatment: NA
Dosage: SUSPENSION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8933097 | CHATTEM SANOFI | Fexofenadine suspension formulation |
Aug, 2030
(5 years from now) |
Drugs and Companies using FEXOFENADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 24 January, 2011
Treatment: NA
Dosage: SUSPENSION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10265311 | BRISTOL-MYERS | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
Jul, 2030
(5 years from now) | |
US10369143 | BRISTOL-MYERS | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
Jul, 2030
(5 years from now) | |
US10369144 | BRISTOL-MYERS | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
Jul, 2030
(5 years from now) | |
US10695339 | BRISTOL-MYERS | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
Jul, 2030
(5 years from now) | |
US10238643 | BRISTOL-MYERS | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
Jul, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Sep 26, 2029 |
Drugs and Companies using TROSPIUM CHLORIDE; XANOMELINE TARTRATE ingredient
NCE-1 date: 26 September, 2028
Market Authorisation Date: 26 September, 2024
Treatment: Treatment of schizophrenia in adults
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8733341 | BOEHRINGER INGELHEIM | Atomizer and method of atomizing fluid with a nozzle rinsing mechanism |
Oct, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Oct 07, 2014 |
Drugs and Companies using ALBUTEROL SULFATE; IPRATROPIUM BROMIDE ingredient
Market Authorisation Date: 07 October, 2011
Treatment: NA
Dosage: SPRAY, METERED
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US11091439 | EXELIXIS | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer |
Jan, 2030
(4 years from now) | |
US8877776 | EXELIXIS | (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
Oct, 2030
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11091440 | EXELIXIS | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer |
Jan, 2030
(4 years from now) | |
US11098015 | EXELIXIS | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer |
Jan, 2030
(4 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Nov 29, 2017 |
Orphan Drug Exclusivity(ODE) | Nov 29, 2019 |
Orphan Drug Exclusivity(ODE-33) | Nov 29, 2019 |
Drugs and Companies using CABOZANTINIB S-MALATE ingredient
NCE-1 date: 29 November, 2016
Market Authorisation Date: 29 November, 2012
Treatment: Method of treating medullary thyroid cancer
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9408837 | PURPLE BIOTECH | Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs |
Feb, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Combination(NC) | May 31, 2021 |
Drugs and Companies using AMLODIPINE BESYLATE; CELECOXIB ingredient
Market Authorisation Date: 31 May, 2018
Treatment: Treatment of adult patients for whom treatment with both amlodipine for hypertension and celecoxib for osteoarthritis are appropriate
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8916195 | NALPROPION | Sustained release formulation of naltrexone |
Feb, 2030
(4 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Combination(NC) | Sep 10, 2017 |
Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 10 September, 2014
Treatment: Use of naltrexone and bupropion in extended-release form for chronic weight management for treating overweight or obesity
Dosage: TABLET, EXTENDED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8232250 | TEVA PHARMS USA | Low frequency glatiramer acetate therapy |
Aug, 2030
(5 years from now) | |
US8399413 | TEVA PHARMS USA | Low frequency glatiramer acetate therapy |
Aug, 2030
(5 years from now) | |
US9155776 | TEVA PHARMS USA | Low frequency glatiramer acetate therapy |
Aug, 2030
(5 years from now) | |
US9402874 | TEVA PHARMS USA | Low frequency glatiramer acetate therapy |
Aug, 2030
(5 years from now) | |
US8969302 | TEVA PHARMS USA | Low frequency glatiramer acetate therapy |
Aug, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-594) | Feb 27, 2012 |
New Product(NP) | Jan 28, 2017 |
Drugs and Companies using GLATIRAMER ACETATE ingredient
Market Authorisation Date: 20 December, 1996
Treatment: Method of treating ms by administering copaxone
Dosage: INJECTABLE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8193182 | SECURA | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
Feb, 2030
(4 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Sep 24, 2023 |
Orphan Drug Exclusivity(ODE-208) | Sep 24, 2025 |
Orphan Drug Exclusivity(ODE-209) | Sep 24, 2025 |
Drugs and Companies using DUVELISIB ingredient
NCE-1 date: 24 September, 2022
Market Authorisation Date: 24 September, 2018
Treatment: NA
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7803839 (Pediatric) | GENENTECH INC | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
May, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Nov 10, 2020 |
Orphan Drug Exclusivity(ODE) | Nov 10, 2022 |
Orphan Drug Exclusivity(ODE-101) | Nov 10, 2022 |
M(M-278) | Jul 28, 2025 |
New Indication(I-902) | Oct 28, 2025 |
Pediatric Exclusivity(PED) | Jan 28, 2026 |
Orphan Drug Exclusivity(ODE-416) | Oct 28, 2029 |
Drugs and Companies using COBIMETINIB FUMARATE ingredient
NCE-1 date: 28 January, 2025
Market Authorisation Date: 10 November, 2015
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9198871 | ABBVIE | Delayed release pancreatin compositions |
Feb, 2030
(4 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-625) | Apr 30, 2013 |
M(M-93) | Jul 29, 2019 |
New Chemical Entity Exclusivity(NCE) | Apr 30, 2014 |
Drugs and Companies using PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) ingredient
NCE-1 date: 30 April, 2013
Market Authorisation Date: 30 April, 2009
Treatment: Treatment of exocrine pancreatic insufficiency
Dosage: CAPSULE, DELAYED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9138456 | CUBIST PHARMS LLC | Lipopeptide compositions and related methods |
Nov, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population(NPP) | Mar 29, 2020 |
M(M-211) | Sep 01, 2020 |
Drugs and Companies using DAPTOMYCIN ingredient
Market Authorisation Date: 12 September, 2003
Treatment: NA
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9138456 | CUBIST PHARMS LLC | Lipopeptide compositions and related methods |
Nov, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population(NPP) | Mar 29, 2020 |
M(M-211) | Sep 01, 2020 |
Drugs and Companies using DAPTOMYCIN ingredient
Market Authorisation Date: 12 September, 2003
Treatment: NA
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8877708 | VEROSCIENCE | Combination of dopamine agonists plus first phase secretagogues for the treatment of metabolic disorders |
Jun, 2030
(5 years from now) | |
US9352025 | VEROSCIENCE | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
Jun, 2030
(5 years from now) | |
US10688155 | VEROSCIENCE | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
Jun, 2030
(5 years from now) | |
US9895422 | VEROSCIENCE | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
Jun, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | May 05, 2012 |
Drugs and Companies using BROMOCRIPTINE MESYLATE ingredient
Market Authorisation Date: 05 May, 2009
Treatment: Treatment of type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue wherein the combined therapeutic effect is greater than the additive effect of administering...
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8173158 | TAKEDA PHARMS USA | Methods of treating gastrointestinal disorders independent of the intake of food |
Mar, 2030
(5 years from now) | |
US8173158 (Pediatric) | TAKEDA PHARMS USA | Methods of treating gastrointestinal disorders independent of the intake of food |
Sep, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Jan 30, 2012 |
Pediatric Exclusivity(PED) | Jul 30, 2012 |
New Patient Population(NPP) | Jul 08, 2019 |
Drugs and Companies using DEXLANSOPRAZOLE ingredient
Market Authorisation Date: 30 January, 2009
Treatment: Healing of all grades of erosive esophagitis (ee) for up to 8 weeks
Dosage: CAPSULE, DELAYED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8563027 | OCULAR THERAPEUTIX | Drug delivery through hydrogel plugs |
Feb, 2030
(4 years from now) | |
US8409606 | OCULAR THERAPEUTIX | Drug delivery through hydrogel plugs |
May, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Nov 30, 2021 |
New Indication(I-800) | Jun 20, 2022 |
New Indication(I-876) | Oct 07, 2024 |
Drugs and Companies using DEXAMETHASONE ingredient
Market Authorisation Date: 30 November, 2018
Treatment: Dextenza is approved for the treatment of ocular pain following ophthalmic surgery
Dosage: INSERT
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9242986 (Pediatric) | VIIV HLTHCARE | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
Jun, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Combination(NC) | Apr 08, 2022 |
New Indication(I-839) | Aug 06, 2023 |
New Patient Population(NPP) | Apr 05, 2027 |
Drugs and Companies using DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient
Market Authorisation Date: 08 April, 2019
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11676691 | VERTICAL PHARMS | Storage and dispensing devices for administration of oral transmucosal dosage forms |
Mar, 2030
(5 years from now) | |
US12033733 | VERTICAL PHARMS | Storage and dispensing devices for administration of oral transmucosal dosage forms |
Mar, 2030
(5 years from now) | |
US8574189 | VERTICAL PHARMS | Storage and dispensing devices for administration of oral transmucosal dosage forms |
Mar, 2030
(5 years from now) | |
US10896751 | VERTICAL PHARMS | Storage and dispensing devices for administration of oral transmucosal dosage forms |
Mar, 2030
(5 years from now) | |
US8202535 | VERTICAL PHARMS | Small-volume oral transmucosal dosage forms |
Oct, 2030
(5 years from now) | |
US8865743 | VERTICAL PHARMS | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
Oct, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Nov 02, 2021 |
Drugs and Companies using SUFENTANIL CITRATE ingredient
Market Authorisation Date: 02 November, 2018
Treatment: Treatment of acute pain
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9169238 | AZURITY | Solid pharmaceutical composition |
Feb, 2030
(4 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Combination(NC) | Dec 20, 2014 |
New Chemical Entity Exclusivity(NCE) | Feb 25, 2016 |
Drugs and Companies using AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE ingredient
NCE-1 date: 25 February, 2015
Market Authorisation Date: 20 December, 2011
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10159681 | LAB HRA PHARMA | Method for on-demand contraception |
Apr, 2030
(5 years from now) | |
US9283233 | LAB HRA PHARMA | Method for on-demand contraception |
Apr, 2030
(5 years from now) | |
US10772897 | LAB HRA PHARMA | Method for on-demand contraception |
Apr, 2030
(5 years from now) | |
US8512745 | LAB HRA PHARMA | Ulipristal acetate tablets |
Jun, 2030
(5 years from now) | |
US8426392 | LAB HRA PHARMA | Method for providing emergency contraception |
Jun, 2030
(5 years from now) | |
US8962603 | LAB HRA PHARMA | Method for post coital contraception in overweight or obese female subjects using ulipristal acetate |
Jun, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Aug 13, 2015 |
M(M-271) | Jun 24, 2024 |
Drugs and Companies using ULIPRISTAL ACETATE ingredient
NCE-1 date: 13 August, 2014
Market Authorisation Date: 13 August, 2010
Treatment: A method for contraception comprising the step of oral administration a dosage of 20 mg to 30 mg of ulipristal acetate to a woman within 72 hours and up to 120 hours after an unprotected intercourse; ...
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8946262 | CUBIST PHARMS | Methods of preventing and treating gastrointestinal dysfunction |
Feb, 2030
(4 years from now) | |
US8112290 | CUBIST PHARMS | Methods for delivering a drug to a hospital patient for short-term use while minimizing long-term use of the drug |
Jul, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | May 20, 2013 |
M(M-128) | Oct 18, 2016 |
Drugs and Companies using ALVIMOPAN ingredient
NCE-1 date: 20 May, 2012
Market Authorisation Date: 20 May, 2008
Treatment: A method to accelerate the time to gastrointestinal recovery by administering about 12 mg of alvimopan to the patient from about 30 to 60 minutes prior to surgery; Accelerating the time to upper and ...
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9284342 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2030
(5 years from now) | |
US8618076 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Dec, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jun 28, 2021 |
New Dosing Schedule(D-177) | Nov 15, 2022 |
New Patient Population(NPP) | Mar 19, 2023 |
New Strength(NS) | Mar 19, 2023 |
M(M-264) | Jul 14, 2023 |
M(M-277) | Apr 27, 2025 |
Orphan Drug Exclusivity(ODE-293) | Mar 19, 2027 |
Orphan Drug Exclusivity(ODE-376) | Jun 10, 2028 |
Pediatric Exclusivity(PED) | Dec 10, 2028 |
Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient
NCE-1 date: 11 December, 2027
Market Authorisation Date: 19 March, 2020
Treatment: For the treatment of hepatitis c
Dosage: TABLET; PELLETS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8445507 | JANSSEN BIOTECH | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases |
Sep, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-808) | Sep 17, 2022 |
New Chemical Entity Exclusivity(NCE) | Feb 14, 2023 |
Drugs and Companies using APALUTAMIDE ingredient
NCE-1 date: 14 February, 2022
Market Authorisation Date: 14 February, 2018
Treatment: Treatment of non-metastatic, castration-resistant prostate cancer (nm-crpc)
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8648098 | GENENTECH INC | Pirfenidone therapy and inducers of cytochrome P450 |
Jan, 2030
(4 years from now) | |
US8318780 | GENENTECH INC | Methods of administering pirfenidone therapy |
Jan, 2030
(4 years from now) | |
US8013002 | GENENTECH INC | Methods of administering pirfenidone therapy |
Jan, 2030
(4 years from now) | |
US7910610 | GENENTECH INC | Methods of administering pirfenidone therapy |
Jan, 2030
(4 years from now) | |
US7816383 | GENENTECH INC | Methods of administering pirfenidone therapy |
Jan, 2030
(4 years from now) | |
US8084475 | GENENTECH INC | Pirfenidone therapy and inducers of cytochrome P450 |
Jan, 2030
(4 years from now) | |
US8754109 | GENENTECH INC | Pirfenidone therapy and inducers of cytochrome P450 |
Jan, 2030
(4 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Oct 15, 2019 |
Orphan Drug Exclusivity(ODE) | Oct 15, 2021 |
Orphan Drug Exclusivity(ODE-77) | Oct 15, 2021 |
Drugs and Companies using PIRFENIDONE ingredient
NCE-1 date: 15 October, 2018
Market Authorisation Date: 11 January, 2017
Treatment: Discontinuing administration of a strong cyp1a2 inducer to avoid reduced pirfenidone efficacy and then administering pirfenidone; Method for administering pirfenidone while avoiding or discontinuing c...
Dosage: TABLET; CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8168614 | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Jan, 2030
(4 years from now) | |
US8168614 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Jul, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Dec 14, 2021 |
New Patient Population(NPP) | Mar 23, 2023 |
Pediatric Exclusivity(PED) | Sep 23, 2023 |
New Dosing Schedule(D-191) | Apr 03, 2026 |
Drugs and Companies using CRISABOROLE ingredient
NCE-1 date: 23 September, 2022
Market Authorisation Date: 14 December, 2016
Treatment: Method of treating mild to moderate atopic dermatitis.
Dosage: OINTMENT
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10864183 | ACROTECH BIOPHARMA | Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same |
May, 2030
(5 years from now) | |
US11020363 | ACROTECH BIOPHARMA | Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same |
May, 2030
(5 years from now) | |
US10940128 | ACROTECH BIOPHARMA | Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same |
Jun, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE) | Mar 10, 2023 |
Orphan Drug Exclusivity(ODE-110) | Mar 10, 2023 |
Drugs and Companies using MELPHALAN HYDROCHLORIDE ingredient
Market Authorisation Date: 10 March, 2016
Treatment: For high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9034300 | GISKIT | Composition and method for medical imaging of body cavities |
Oct, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Nov 07, 2024 |
Drugs and Companies using AIR POLYMER-TYPE A ingredient
NCE-1 date: 08 November, 2023
Market Authorisation Date: 07 November, 2019
Treatment: Use in sonohysterosalpinography to assess fallopian tube patency
Dosage: FOAM
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10688071 | MAYNE PHARMA | Topical foam composition |
Feb, 2030
(5 years from now) | |
US8808716 | MAYNE PHARMA | Topical foam composition |
Feb, 2030
(5 years from now) | |
US10568859 | MAYNE PHARMA | Topical foam composition |
Feb, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosage Form(NDF) | May 11, 2015 |
Drugs and Companies using TAZAROTENE ingredient
Market Authorisation Date: 11 May, 2012
Treatment: Topical treatment of acne vulgaris in patients 12 years of age or older
Dosage: AEROSOL, FOAM
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9157121 | VANDA PHARMS INC | Method of treatment based on polymorphisms of the KCNQ1 gene |
Apr, 2030
(5 years from now) | |
US8652776 | VANDA PHARMS INC | Prediction of QT prolongation based on SNP genotype |
Aug, 2030
(5 years from now) | |
US8999638 | VANDA PHARMS INC | Method of treatment based on polymorphisms of the KCNQ1 gene |
Oct, 2030
(5 years from now) | |
US9074255 | VANDA PHARMS INC | Method of predicting a predisposition to QT prolongation |
Dec, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | May 06, 2014 |
M(M-180) | May 26, 2019 |
New Indication(I-939) | Apr 02, 2027 |
Drugs and Companies using ILOPERIDONE ingredient
NCE-1 date: 06 May, 2013
Market Authorisation Date: 06 May, 2009
Treatment: Dosage modification to reduce risks associated with qt prolongation not induced by other drugs during treatment with iloperidone; Dosage modification to reduce the risk associated with qt prolongation...
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8721615 | ASTRAZENECA AB | Ampoule comprising an ampoule holder |
Jan, 2030
(4 years from now) | |
US8685934 | ASTRAZENECA AB | Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof |
May, 2030
(5 years from now) | |
US7919598 (Pediatric) | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2030
(5 years from now) | |
US8721615 (Pediatric) | ASTRAZENECA AB | Ampoule comprising an ampoule holder |
Jul, 2030
(5 years from now) | |
US8685934 (Pediatric) | ASTRAZENECA AB | Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof |
Nov, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-157) | Mar 11, 2018 |
New Chemical Entity Exclusivity(NCE) | Jan 08, 2019 |
M(M-212) | Oct 20, 2020 |
M(M-238) | Feb 22, 2022 |
New Indication(I-841) | Oct 18, 2022 |
New Indication(I-834) | May 05, 2023 |
New Indication(I-857) | Apr 30, 2024 |
M(M-298) | May 08, 2026 |
New Patient Population(NPP) | Jun 12, 2027 |
Pediatric Exclusivity(PED) | Dec 12, 2027 |
Drugs and Companies using DAPAGLIFLOZIN ingredient
NCE-1 date: 12 December, 2026
Market Authorisation Date: 08 January, 2014
Treatment: Treatment of type 2 diabetes mellitus in a patient, wherein glycemic control (hba1c < 7.0%) is not achievable using one or more of insulin, metformin, pioglitazone, or rosiglitazone
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8324157 | NOVO | Preparation comprising insulin, nicotinamide and an amino acid |
Jun, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Sep 29, 2020 |
M(M-247) | Oct 21, 2022 |
New Patient Population(NPP) | Dec 19, 2022 |
Drugs and Companies using INSULIN ASPART ingredient
Market Authorisation Date: 29 September, 2017
Treatment: NA
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8324157 | NOVO | Preparation comprising insulin, nicotinamide and an amino acid |
Jun, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Sep 29, 2020 |
New Patient Population(NPP) | Dec 19, 2022 |
Drugs and Companies using INSULIN ASPART ingredient
Market Authorisation Date: 29 September, 2017
Treatment: NA
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9993461 | TRAVERE | Method for treating disorders associated with glomerular function |
Mar, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Feb 17, 2028 |
Orphan Drug Exclusivity(ODE-389) | Feb 17, 2030 |
Orphan Drug Exclusivity(ODE-493) | Sep 05, 2031 |
Drugs and Companies using SPARSENTAN ingredient
NCE-1 date: 17 February, 2027
Market Authorisation Date: 17 February, 2023
Treatment: Treatment of primary immunoglobulin a nephropathy (igan) in adults at risk for disease progression
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9352041 | CHIESI | Use of an oleogel containing triterpene for healing wounds |
Nov, 2030
(5 years from now) | |
US9827214 | CHIESI | Use of an oleogel containing triterpene for healing wounds |
Nov, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Dec 18, 2028 |
Orphan Drug Exclusivity(ODE-460) | Dec 18, 2030 |
Drugs and Companies using BIRCH TRITERPENES ingredient
NCE-1 date: 19 December, 2027
Market Authorisation Date: 18 December, 2023
Treatment: Use of birch triterpenes for the treatment of wounds associated with dystrophic and junctional epidermolysis bullosa
Dosage: GEL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9597289 | SALERNO PHARMS | Liquid oral simvastatin compositions |
Feb, 2030
(5 years from now) |
Drugs and Companies using SIMVASTATIN ingredient
Market Authorisation Date: 21 April, 2016
Treatment: NA
Dosage: SUSPENSION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8980327 | TAKEDA PHARMS USA | Capsule and powder formulations containing lanthanum compounds |
Dec, 2030
(5 years from now) | |
US9023397 | TAKEDA PHARMS USA | Capsule and powder formulations containing lanthanum compounds |
Dec, 2030
(5 years from now) |
Drugs and Companies using LANTHANUM CARBONATE ingredient
Market Authorisation Date: 24 September, 2014
Treatment: NA
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10206887 | AADI | Prion free nanoparticle compositions and methods of making thereof |
Apr, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Nov 22, 2024 |
Orphan Drug Exclusivity(ODE-386) | Nov 22, 2028 |
Drugs and Companies using SIROLIMUS ingredient
Market Authorisation Date: 22 November, 2021
Treatment: NA
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8247415 | UROVANT | Hydroxymethyl pyrrolidines as β3 adrenergic receptor agonists |
Dec, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Dec 23, 2025 |
Drugs and Companies using VIBEGRON ingredient
NCE-1 date: 23 December, 2024
Market Authorisation Date: 23 December, 2020
Treatment: Treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11103669 | VERO BIOTECH INC | Nitric oxide therapies |
Jun, 2030
(5 years from now) | |
US8607785 | VERO BIOTECH INC | Systems and devices for generating nitric oxide |
Jul, 2030
(5 years from now) |
Drugs and Companies using NITRIC OXIDE ingredient
Market Authorisation Date: 20 December, 2019
Treatment: NA
Dosage: GAS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8148374 (Pediatric) | GILEAD SCIENCES INC | Modulators of pharmacokinetic properties of therapeutics |
Mar, 2030
(5 years from now) | |
US9891239 (Pediatric) | GILEAD SCIENCES INC | Modulators of pharmacokinetic properties of therapeutics |
Mar, 2030
(5 years from now) | |
US8633219 | GILEAD SCIENCES INC | Combination therapy |
Apr, 2030
(5 years from now) | |
US8633219 (Pediatric) | GILEAD SCIENCES INC | Combination therapy |
Oct, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population(NPP) | Sep 25, 2020 |
New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
New Dosing Schedule(D-173) | Dec 10, 2021 |
NCE-1 date: 06 November, 2019
Market Authorisation Date: 05 November, 2015
Treatment: Treatment of hiv infection
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9572856 | LA JOLLA PHARMA | Method of treating low blood pressure |
Nov, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Dec 21, 2022 |
Drugs and Companies using ANGIOTENSIN II ACETATE ingredient
NCE-1 date: 21 December, 2021
Market Authorisation Date: 23 December, 2021
Treatment: Treating refractory hypotension with about 20 ng/kg/min angiotensin ii in a patient receiving vasopressor
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8426586 (Pediatric) | BOEHRINGER INGELHEIM | Process for preparing amino crotonyl compounds |
Apr, 2030
(5 years from now) | |
US8545884 (Pediatric) | BOEHRINGER INGELHEIM | Solid pharmaceutical formulations comprising BIBW 2992 |
Jun, 2030
(5 years from now) | |
US10004743 | BOEHRINGER INGELHEIM | Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient |
Jul, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jul 12, 2018 |
New Indication(I-730) | Apr 15, 2019 |
Orphan Drug Exclusivity(ODE-50) | Jul 12, 2020 |
New Indication(I-763) | Jan 12, 2021 |
Orphan Drug Exclusivity(ODE) | Apr 15, 2023 |
Orphan Drug Exclusivity(ODE-115) | Apr 15, 2023 |
Orphan Drug Exclusivity(ODE-230) | Jan 12, 2025 |
M(M-276) | Apr 07, 2025 |
Pediatric Exclusivity(PED) | Oct 07, 2025 |
Drugs and Companies using AFATINIB DIMALEATE ingredient
NCE-1 date: 07 October, 2024
Market Authorisation Date: 12 July, 2013
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8334281 | EVOKE PHARMA INC | Nasal formulations of metoclopramide |
May, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Jun 19, 2023 |
Drugs and Companies using METOCLOPRAMIDE HYDROCHLORIDE ingredient
Market Authorisation Date: 19 June, 2020
Treatment: Nasal administration of metoclopramide for treatment of diabetic gastroparesis
Dosage: SPRAY, METERED
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US12115179 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Feb, 2030
(4 years from now) | |
US8551957 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate |
Apr, 2030
(5 years from now) | |
US8846695 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
Jun, 2030
(5 years from now) | |
US10406172 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Jun, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Combination(NC) | Jan 30, 2018 |
New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
New Indication(I-739) | Dec 02, 2019 |
M(M-258) | Jul 03, 2022 |
M(M-252) | Mar 30, 2023 |
Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN ingredient
NCE-1 date: 01 August, 2018
Market Authorisation Date: 30 January, 2015
Treatment: Treatment of type 2 diabetes mellitus by administration of empagliflozin, linagliptin and metformin; Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagl...
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9867792 | SUPERNUS PHARMS | Method of administering amantadine prior to a sleep period |
Dec, 2030
(5 years from now) | |
US9867793 | SUPERNUS PHARMS | Method of administering amantadine prior to a sleep period |
Dec, 2030
(5 years from now) | |
US11197835 | SUPERNUS PHARMS | Method of administering amantadine prior to a sleep period |
Dec, 2030
(5 years from now) | |
US8741343 | SUPERNUS PHARMS | Method of administering amantadine prior to a sleep period |
Dec, 2030
(5 years from now) | |
US9877933 | SUPERNUS PHARMS | Method of administering amantadine prior to a sleep period |
Dec, 2030
(5 years from now) | |
US9867791 | SUPERNUS PHARMS | Method of administering amantadine prior to a sleep period |
Dec, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-769) | Aug 24, 2020 |
New Product(NP) | Aug 24, 2020 |
Orphan Drug Exclusivity(ODE) | Aug 24, 2024 |
Orphan Drug Exclusivity(ODE-153) | Aug 24, 2024 |
Drugs and Companies using AMANTADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 24 August, 2017
Treatment: Treatment of dyskinesia in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications; Treatment of dyskinesia and increasing on time with...
Dosage: CAPSULE, EXTENDED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8822430 | GILEAD SCIENCES INC | Antiviral compounds |
May, 2030
(5 years from now) | |
US8088368 | GILEAD SCIENCES INC | Antiviral compounds |
May, 2030
(5 years from now) | |
US9284342 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2030
(5 years from now) | |
US8618076 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Dec, 2030
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8273341 | GILEAD SCIENCES INC | Antiviral compounds |
May, 2030
(5 years from now) | |
US8841278 | GILEAD SCIENCES INC | Antiviral compounds |
May, 2030
(5 years from now) | |
US9511056 | GILEAD SCIENCES INC | Antiviral compounds |
May, 2030
(5 years from now) | |
US8822430 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2030
(5 years from now) | |
US9511056 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2030
(5 years from now) | |
US8841278 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2030
(5 years from now) | |
US8088368 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2030
(5 years from now) | |
US8273341 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosing Schedule(D-153) | Nov 12, 2018 |
New Indication(I-718) | Nov 12, 2018 |
New Indication(I-719) | Nov 12, 2018 |
New Indication(I-720) | Nov 12, 2018 |
New Dosing Schedule(D-158) | Feb 12, 2019 |
New Dosing Schedule(D-159) | Feb 12, 2019 |
New Dosing Schedule(D-160) | Feb 12, 2019 |
New Chemical Entity Exclusivity(NCE) | Oct 10, 2019 |
New Patient Population(NPP) | Apr 07, 2020 |
New Dosing Schedule(D-177) | Nov 15, 2022 |
Orphan Drug Exclusivity(ODE) | Apr 07, 2024 |
ODE*(ODE*) | Aug 28, 2026 |
Orphan Drug Exclusivity(ODE-136) | Apr 07, 2024 |
Pediatric Exclusivity(PED) | Oct 07, 2024 |
Orphan Drug Exclusivity(ODE-262) | Aug 28, 2026 |
Orphan Drug Exclusivity(ODE-263) | Aug 28, 2026 |
Orphan Drug Exclusivity(ODE-264) | Aug 28, 2026 |
Drugs and Companies using LEDIPASVIR; SOFOSBUVIR ingredient
Market Authorisation Date: 28 August, 2019
Treatment: For the treatment of hepatitis c
Dosage: PELLETS; TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9006281 | ARDELYX INC | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
May, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Sep 12, 2024 |
Drugs and Companies using TENAPANOR HYDROCHLORIDE ingredient
NCE-1 date: 13 September, 2023
Market Authorisation Date: 12 September, 2019
Treatment: Method of treating irritable bowel syndrome with constipation by administering tenapanor
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10610125 | BRISTOL MYERS SQUIBB | Methods and compositions for cell-proliferation-related disorders |
Jun, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Aug 01, 2022 |
Orphan Drug Exclusivity(ODE) | Aug 01, 2024 |
Orphan Drug Exclusivity(ODE-151) | Aug 01, 2024 |
Drugs and Companies using ENASIDENIB MESYLATE ingredient
NCE-1 date: 01 August, 2021
Market Authorisation Date: 01 August, 2017
Treatment: Treatment of relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10206813 | GLAUKOS | Implants with controlled drug delivery features and methods of using same |
Oct, 2030
(5 years from now) | |
US11426306 | GLAUKOS | Implants with controlled drug delivery features and methods of using same |
Oct, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Dec 13, 2026 |
Drugs and Companies using TRAVOPROST ingredient
Market Authorisation Date: 13 December, 2023
Treatment: NA
Dosage: IMPLANT
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9662398 | HARROW EYE | Carboxylvinyl polymer-containing nanoparticle suspensions |
Dec, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Oct 16, 2015 |
Drugs and Companies using NEPAFENAC ingredient
Market Authorisation Date: 16 October, 2012
Treatment: NA
Dosage: SUSPENSION/DROPS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9757552 | ORGANON | Applicator for inserting an implant |
Jul, 2030
(5 years from now) |
Drugs and Companies using ETONOGESTREL ingredient
Market Authorisation Date: 17 July, 2006
Treatment: Prevention of pregnancy
Dosage: IMPLANT
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9956231 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(5 years from now) | |
US10064875 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(5 years from now) | |
US10588914 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Nov 28, 2020 |
Drugs and Companies using CLOBETASOL PROPIONATE ingredient
Market Authorisation Date: 28 November, 2017
Treatment: Plaque psoriasis; Twice daily topical treatment of moderate to severe plaque psoriasis.; Treatment of moderate to severe plaque psoriasis in patients 18 years of age or older
Dosage: CREAM
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8534281 | GLAXO GRP ENGLAND | Manifold for use in medicament dispenser |
Mar, 2030
(5 years from now) | |
US8746242 | GLAXO GRP ENGLAND | Medicament dispenser |
Oct, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Dec 18, 2018 |
M(M-172) | Feb 24, 2019 |
M(M-245) | Jun 09, 2022 |
Drugs and Companies using UMECLIDINIUM BROMIDE ingredient
NCE-1 date: 18 December, 2017
Market Authorisation Date: 30 April, 2014
Treatment: NA
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8791140 | PF PRISM CV | Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyondazole suitable for the treatment of abnormal cell growth in mammals |
Dec, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jan 27, 2017 |
Drugs and Companies using AXITINIB ingredient
NCE-1 date: 28 January, 2016
Market Authorisation Date: 27 January, 2012
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8217156 | LEXICON PHARMS INC | Solid forms of (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol and methods of their use |
Oct, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | May 26, 2028 |
Drugs and Companies using SOTAGLIFLOZIN ingredient
NCE-1 date: 27 May, 2027
Market Authorisation Date: 26 May, 2023
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8268800 | OTSUKA | Certain compounds, compositions and methods |
Aug, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jul 07, 2025 |
Orphan Drug Exclusivity(ODE-316) | Jul 07, 2027 |
Drugs and Companies using CEDAZURIDINE; DECITABINE ingredient
NCE-1 date: 07 July, 2024
Market Authorisation Date: 07 July, 2020
Treatment: Method for inhibiting degradation of a cda substrate by administering cedazuridine
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8957054 | MILLICENT | Pharmaceutical compositions |
Jan, 2030
(4 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Nov 16, 2021 |
Drugs and Companies using PRASTERONE ingredient
NCE-1 date: 16 November, 2020
Market Authorisation Date: 16 November, 2016
Treatment: Intravaginal prasterone (dehydroepiandrosterone) at a daily dose of 6.5mg for the treatment of dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause
Dosage: INSERT
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11576894 | JANSSEN PHARMS | Combination therapy for the treatment of diabetes |
Jul, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Combination(NC) | Aug 08, 2017 |
New Chemical Entity Exclusivity(NCE) | Mar 29, 2018 |
New Indication(I-735) | May 20, 2019 |
M(M-197) | Feb 01, 2020 |
New Indication(I-788) | Oct 29, 2021 |
Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 29 March, 2017
Market Authorisation Date: 08 August, 2014
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8771733 | MSD SUB MERCK | Pharmaceutical composition containing an anti-nucleating agent |
Jun, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Oct 12, 2012 |
New Dosage Form(NDF) | Dec 20, 2016 |
New Patient Population(NPP) | Nov 22, 2020 |
M(M-114) | Mar 28, 2015 |
New Dosing Schedule(D-167) | May 26, 2020 |
Pediatric Exclusivity(PED) | May 22, 2021 |
Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient
Market Authorisation Date: 21 December, 2011
Treatment: Treatment of hiv infection
Dosage: TABLET, CHEWABLE; TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8771733 | MSD SUB MERCK | Pharmaceutical composition containing an anti-nucleating agent |
Jun, 2030
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9649311 | MSD SUB MERCK | Solid pharmaceutical compositions containing an integrase inhibitor |
Oct, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Strength(NS) | May 26, 2020 |
New Patient Population(NPP) | Nov 22, 2020 |
Pediatric Exclusivity(PED) | May 22, 2021 |
Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient
NCE-1 date: 22 May, 2020
Market Authorisation Date: 12 October, 2007
Treatment: Treatment of hiv infection
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8242104 | GENENTECH INC | Benzoxazepin P13K inhibitor compounds and methods of use |
Sep, 2030
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8343955 | GENENTECH INC | Benzoxazepin PI3K inhibitor compounds and methods of use |
Sep, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Oct 10, 2029 |
Drugs and Companies using INAVOLISIB ingredient
NCE-1 date: 10 October, 2028
Market Authorisation Date: 10 October, 2024
Treatment: Combination with palbociclib and fulvestrant for treatment of adults with endocrine-resistant pik3ca-mutated hr-positive her2-negative locally advanced or metastatic breast cancer following recurrence...
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US12115179 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Feb, 2030
(4 years from now) | |
US8551957 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate |
Apr, 2030
(5 years from now) | |
US10406172 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Jun, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-159) | Jun 26, 2018 |
M(M-160) | Jun 26, 2018 |
M(M-161) | Jun 26, 2018 |
M(M-174) | Mar 18, 2019 |
New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
New Indication(I-739) | Dec 02, 2019 |
New Indication(I-869) | Aug 18, 2024 |
M(M-82) | Feb 24, 2025 |
Pediatric Exclusivity(PED) | Dec 20, 2026 |
New Patient Population(NPP) | Jun 20, 2026 |
New Indication(I-922) | Sep 21, 2026 |
Drugs and Companies using EMPAGLIFLOZIN ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 01 August, 2014
Treatment: Treatment of type 2 diabetes mellitus by administration of empagliflozin, linagliptin and metformin; Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagl...
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US10617696 | TOLMAR | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
Apr, 2030
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10543219 | TOLMAR | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
Apr, 2030
(5 years from now) | |
US8778916 | TOLMAR | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
Apr, 2030
(5 years from now) | |
US11426416 | TOLMAR | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
Apr, 2030
(5 years from now) | |
US11179403 | TOLMAR | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
Apr, 2030
(5 years from now) | |
US8492369 | TOLMAR | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
Dec, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Mar 27, 2022 |
Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient
Market Authorisation Date: 27 March, 2019
Treatment: Method of treating testosterone deficiency; A method of treating testosterone deficiency in men
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11911388 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug |
Apr, 2030
(5 years from now) | |
US9155705 | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
May, 2030
(5 years from now) | |
US8846695 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
Jun, 2030
(5 years from now) | |
US9155705 (Pediatric) | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Nov, 2030
(5 years from now) | |
US8846695 (Pediatric) | BOEHRINGER INGELHEIM | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
Dec, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Combination(NC) | Jan 30, 2015 |
New Chemical Entity Exclusivity(NCE) | May 02, 2016 |
M(M-146) | Jul 30, 2017 |
M(M-258) | Jul 03, 2022 |
M(M-252) | Mar 30, 2023 |
M(M-295) | Jun 20, 2026 |
Pediatric Exclusivity(PED) | Dec 20, 2026 |
Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 30 January, 2012
Treatment: Linagliptin (5 mg daily dose) and metformin (with or without insulin) for treating type 2 diabetes patients with renal impairment and insufficient glycemic control despite previous treatment with metf...
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11911388 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug |
Apr, 2030
(5 years from now) | |
US9155705 | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
May, 2030
(5 years from now) | |
US8846695 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
Jun, 2030
(5 years from now) | |
US9155705 (Pediatric) | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Nov, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-258) | Jul 03, 2022 |
M(M-252) | Mar 30, 2023 |
M(M-295) | Jun 20, 2026 |
Pediatric Exclusivity(PED) | Dec 20, 2026 |
Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 27 May, 2016
Treatment: Linagliptin (5 mg daily dose) and metformin (with or without insulin) for treating type 2 diabetes patients with renal impairment and insufficient glycemic control despite previous treatment with metf...
Dosage: TABLET, EXTENDED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10583110 | SANOFI AVENTIS US | Antitumoral use of cabazitaxel |
Oct, 2030
(5 years from now) | |
US10716777 | SANOFI AVENTIS US | Antitumoral use of cabazitaxel |
Oct, 2030
(5 years from now) | |
US8927592 | SANOFI AVENTIS US | Antitumoral use of cabazitaxel |
Oct, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jun 17, 2015 |
M(M-201) | May 17, 2020 |
M(M-209) | Sep 14, 2020 |
Pediatric Exclusivity(PED) | Nov 17, 2020 |
M(M-128) | Dec 18, 2023 |
Drugs and Companies using CABAZITAXEL ingredient
NCE-1 date: 18 November, 2019
Market Authorisation Date: 17 June, 2010
Treatment: Increasing survival in metastatic castration-resistant prostate cancer patients previously treated with docetaxel by administering as a 3 week cycle cabazitaxel after 5 mg dexchlorpheniramine, 8 mg de...
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8039494 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jul, 2030
(5 years from now) | |
US9861698 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jul, 2030
(5 years from now) | |
US10105444 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jul, 2030
(5 years from now) | |
US8486978 | BAUSCH | Compositions and methods for treating diseases of the nail |
Oct, 2030
(5 years from now) | |
US9302009 | BAUSCH | Compositions and methods for treating diseases of the nail |
Oct, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jun 06, 2019 |
New Patient Population(NPP) | Apr 27, 2023 |
Drugs and Companies using EFINACONAZOLE ingredient
NCE-1 date: 06 June, 2018
Market Authorisation Date: 06 June, 2014
Treatment: Antimycotic uses, specifically treatment of onychomycosis
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9242986 (Pediatric) | VIIV HLTHCARE | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
Jun, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Aug 12, 2018 |
New Combination(NC) | Nov 21, 2020 |
Drugs and Companies using DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE ingredient
NCE-1 date: 12 August, 2017
Market Authorisation Date: 21 November, 2017
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10905694 | OTSUKA | Pharmaceutical solid preparation comprising benzazepines and production method thereof |
Apr, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-779) | Apr 23, 2021 |
Orphan Drug Exclusivity(ODE-178) | Apr 23, 2025 |
Drugs and Companies using TOLVAPTAN ingredient
Market Authorisation Date: 23 April, 2018
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9427448 | CHIESI | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
Nov, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jun 22, 2020 |
Drugs and Companies using CANGRELOR ingredient
NCE-1 date: 23 June, 2019
Market Authorisation Date: 22 June, 2015
Treatment: Method of treating, reducing the incidence of, or preventing an ischemic event in a patient undergoing pci by administering intravenously 30 ug/kg bolus before pci and continuous infusion of 4 ug/kg/m...
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9682061 | MELINTA THERAP | Methods of treating bacterial infections using oritavancin |
Apr, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Aug 06, 2019 |
New Product(NP) | Mar 12, 2024 |
Generating Antibiotic Incentives Now(GAIN) | Aug 06, 2024 |
Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient
NCE-1 date: 07 August, 2023
Market Authorisation Date: 12 March, 2021
Treatment: Treatment of acute bacterial skin and skin structure infections with a single dose of 1200mg oritavancin or its single dose equivalent
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8685980 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
May, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-783) | Jul 18, 2021 |
New Indication(I-784) | Jul 18, 2021 |
New Chemical Entity Exclusivity(NCE) | Mar 13, 2022 |
New Patient Population(NPP) | Dec 10, 2024 |
New Indication(I-950) | Sep 17, 2027 |
Drugs and Companies using RIBOCICLIB SUCCINATE ingredient
NCE-1 date: 13 March, 2021
Market Authorisation Date: 13 March, 2017
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8685980 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
May, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Mar 13, 2022 |
New Patient Population(NPP) | Dec 10, 2024 |
New Indication(I-951) | Sep 17, 2027 |
Drugs and Companies using LETROZOLE; RIBOCICLIB SUCCINATE ingredient
NCE-1 date: 13 March, 2021
Market Authorisation Date: 04 May, 2017
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9308191 | ST RENATUS | Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration |
Apr, 2030
(5 years from now) | |
US8580282 | ST RENATUS | Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration |
Apr, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Combination(NC) | Jun 29, 2019 |
Drugs and Companies using OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE ingredient
Market Authorisation Date: 29 June, 2016
Treatment: Method of anesthetizing at least a portion of the maxillary dental arch
Dosage: SPRAY, METERED
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10500214 | ABBVIE | Formulations of deoxycholic acid and salts thereof |
Mar, 2030
(5 years from now) | |
US8101593 | ABBVIE | Formulations of deoxycholic acid and salts thereof |
Mar, 2030
(5 years from now) | |
US8653058 | ABBVIE | Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits |
Mar, 2030
(5 years from now) | |
US8367649 | ABBVIE | Formulations of deoxycholic acid and salts thereof |
Mar, 2030
(5 years from now) |
Drugs and Companies using DEOXYCHOLIC ACID ingredient
Market Authorisation Date: 29 April, 2015
Treatment: NA
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9669021 | SUMITOMO PHARMA AM | Sublingual apomorphine |
Jun, 2030
(5 years from now) | |
US10420763 | SUMITOMO PHARMA AM | Sublingual apomorphine |
Jun, 2030
(5 years from now) | |
US9669019 | SUMITOMO PHARMA AM | Sublingual apomorphine |
Jun, 2030
(5 years from now) | |
US9283219 | SUMITOMO PHARMA AM | Sublingual films |
Jun, 2030
(5 years from now) | |
US9044475 | SUMITOMO PHARMA AM | Sublingual apomorphine |
Jun, 2030
(5 years from now) | |
US9326981 | SUMITOMO PHARMA AM | Sublingual apomorphine |
Jun, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | May 21, 2023 |
Drugs and Companies using APOMORPHINE HYDROCHLORIDE ingredient
Market Authorisation Date: 21 May, 2020
Treatment: Treatment of 'off' episodes in patients with parkinson's disease
Dosage: FILM
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10576090 | MARIUS PHARMS LLC | Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols |
Dec, 2030
(5 years from now) | |
US11590146 | MARIUS PHARMS LLC | Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols |
Dec, 2030
(5 years from now) | |
US10576089 | MARIUS PHARMS LLC | Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols |
Dec, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Jul 27, 2025 |
Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient
Market Authorisation Date: 27 July, 2022
Treatment: Method of treating testosterone deficiency
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9789270 | SUMITOMO PHARMA AM | Inhalation therapy device comprising an ampoule for storing a medicament to be nebulized |
Oct, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Dec 05, 2020 |
Drugs and Companies using GLYCOPYRROLATE ingredient
Market Authorisation Date: 05 December, 2017
Treatment: NA
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9259425 | BAUSCH AND LOMB INC | Compositions and methods for eye whitening |
Jul, 2030
(5 years from now) | |
US8293742 | BAUSCH AND LOMB INC | Preferential vasoconstriction compositions and methods of use |
Jul, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Dec 22, 2020 |
Drugs and Companies using BRIMONIDINE TARTRATE ingredient
Market Authorisation Date: 22 December, 2017
Treatment: Relieves redness of the eye due to minor eye irritations
Dosage: SOLUTION/DROPS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8293742 | BAUSCH AND LOMB INC | Preferential vasoconstriction compositions and methods of use |
Jul, 2030
(5 years from now) | |
US9259425 | BAUSCH AND LOMB INC | Compositions and methods for eye whitening |
Jul, 2030
(5 years from now) |
Drugs and Companies using BRIMONIDINE TARTRATE ingredient
Market Authorisation Date: 19 April, 2024
Treatment: Relieves redness of the eye due to minor eye irritations
Dosage: SOLUTION/DROPS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10028937 | ABBVIE | Anti-viral compounds |
Jun, 2030
(5 years from now) | |
US10039754 | ABBVIE | Anti-viral compounds |
Jun, 2030
(5 years from now) | |
US9586978 | ABBVIE | Anti-viral compounds |
Nov, 2030
(5 years from now) | |
US10039754 (Pediatric) | ABBVIE | Anti-viral compounds |
Dec, 2030
(5 years from now) | |
US10028937 (Pediatric) | ABBVIE | Anti-viral compounds |
Dec, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-230) | Aug 06, 2021 |
New Patient Population(NPP) | Apr 30, 2022 |
New Chemical Entity Exclusivity(NCE) | Aug 03, 2022 |
New Dosing Schedule(D-175) | Sep 26, 2022 |
M(M-259) | Apr 10, 2023 |
Orphan Drug Exclusivity(ODE-232) | Apr 30, 2026 |
Orphan Drug Exclusivity(ODE-233) | Apr 30, 2026 |
Orphan Drug Exclusivity(ODE-372) | Jun 10, 2028 |
Pediatric Exclusivity(PED) | Dec 10, 2028 |
Drugs and Companies using GLECAPREVIR; PIBRENTASVIR ingredient
NCE-1 date: 11 December, 2027
Market Authorisation Date: 10 June, 2021
Treatment: Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in adult and pediatric patients 12 years and older or weighing at least 45 kg; Treatment of chronic hepatitis c virus (hcv) ge...
Dosage: PELLETS; TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8492441 | NOVARTIS | Dosage regimen of an S1P receptor agonist |
Nov, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Mar 26, 2024 |
M(M-274) | Mar 01, 2025 |
Drugs and Companies using SIPONIMOD ingredient
NCE-1 date: 27 March, 2023
Market Authorisation Date: 26 March, 2019
Treatment: A method of treating multiple sclerosis by administering siponimod using a titration scheme to reach a maintenance dose
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8703781 | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors |
Oct, 2030
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8952018 | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors |
Oct, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-678) | Jan 08, 2017 |
New Chemical Entity Exclusivity(NCE) | May 29, 2018 |
M(M-170) | Nov 20, 2018 |
Orphan Drug Exclusivity(ODE) | May 29, 2020 |
Orphan Drug Exclusivity(ODE-48) | May 29, 2020 |
New Indication(I-745) | Jun 22, 2020 |
Orphan Drug Exclusivity(ODE-57) | Jan 08, 2021 |
New Indication(I-778) | Apr 30, 2021 |
New Indication(I-781) | May 04, 2021 |
M(M-246) | Oct 06, 2022 |
Orphan Drug Exclusivity(ODE-148) | Jun 22, 2024 |
Orphan Drug Exclusivity(ODE-182) | Apr 30, 2025 |
Orphan Drug Exclusivity(ODE-183) | May 04, 2025 |
New Indication(I-895) | Jun 22, 2025 |
Pediatric Exclusivity(PED) | Sep 16, 2026 |
New Indication(I-908) | Mar 16, 2026 |
New Product(NP) | Mar 16, 2026 |
Orphan Drug Exclusivity(ODE-428) | Mar 16, 2030 |
Drugs and Companies using TRAMETINIB DIMETHYL SULFOXIDE ingredient
NCE-1 date: 22 December, 2024
Market Authorisation Date: 29 May, 2013
Treatment: Mekinist is indicated, in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with braf v600e mutation as detected by an fda-approved test
Dosage: TABLET; SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9850229 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(5 years from now) | |
US9593100 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(5 years from now) | |
US10005761 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jun 27, 2023 |
Orphan Drug Exclusivity(ODE-194) | Jun 27, 2025 |
New Indication(I-928) | Oct 11, 2026 |
Drugs and Companies using BINIMETINIB ingredient
NCE-1 date: 27 June, 2022
Market Authorisation Date: 27 June, 2018
Treatment: Indicated in combination with encorafenib for the treatment of melanoma with a braf mutation; Mektovi is a kinase inhibitor indicated in combination with encorafenib, for the treatment of patients wit...
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8580293 | FERRING PHARMS INC | Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof |
Jan, 2030
(4 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Apr 29, 2023 |
Drugs and Companies using PROGESTERONE ingredient
Market Authorisation Date: 29 April, 2020
Treatment: Method of supporting embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an assisted reproductive technology (art) treatment program for infertile women
Dosage: SYSTEM
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8231906 | NOVEN | Transdermal estrogen device and delivery |
Jul, 2030
(5 years from now) |
Drugs and Companies using ESTRADIOL ingredient
Market Authorisation Date: 23 September, 2014
Treatment: NA
Dosage: FILM, EXTENDED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8530668 | VANCOCIN ITALIA | Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor |
Jan, 2030
(4 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jul 31, 2023 |
Drugs and Companies using LUSUTROMBOPAG ingredient
NCE-1 date: 31 July, 2022
Market Authorisation Date: 31 July, 2018
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9549999 | MEDI-PHYSICS | Radiopharmaceutical composition |
Mar, 2030
(5 years from now) |
Drugs and Companies using TECHNETIUM TC-99M TETROFOSMIN KIT ingredient
Market Authorisation Date: 09 February, 1996
Treatment: NA
Dosage: INJECTABLE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10842780 (Pediatric) | APGDI | Pharmaceutical composition for modified release |
Mar, 2030
(5 years from now) | |
US11707451 (Pediatric) | APGDI | Pharmaceutical composition for modified release |
Mar, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jun 28, 2017 |
New Indication(I-777) | Apr 27, 2021 |
New Indication(I-855) | Mar 25, 2024 |
Pediatric Exclusivity(PED) | Sep 25, 2024 |
Drugs and Companies using MIRABEGRON ingredient
NCE-1 date: 26 September, 2023
Market Authorisation Date: 28 June, 2012
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7399865 | PUMA BIOTECH | Protein tyrosine kinase enzyme inhibitors |
Dec, 2030
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9211291 | PUMA BIOTECH | Treatment regimen utilizing neratinib for breast cancer |
Mar, 2030
(5 years from now) | |
US8790708 | PUMA BIOTECH | Coated tablet formulations and uses thereof |
Nov, 2030
(5 years from now) | |
US8518446 | PUMA BIOTECH | Coated tablet formulations and uses thereof |
Nov, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jul 17, 2022 |
New Indication(I-823) | Feb 25, 2023 |
New Dosing Schedule(D-182) | Jun 28, 2024 |
Drugs and Companies using NERATINIB MALEATE ingredient
NCE-1 date: 17 July, 2021
Market Authorisation Date: 17 July, 2017
Treatment: Extended adjuvant treatment of adult patients with early-stage human epidermal growth factor receptor 2 (her2)-positive breast cancer, to follow adjuvant trastuzumab based therapy; Use in combination ...
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10350174 | UCB INC | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
Dec, 2030
(5 years from now) | |
US10130589 | UCB INC | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
Dec, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | May 09, 2012 |
New Indication(I-646) | Apr 02, 2015 |
New Indication(I-647) | Apr 02, 2015 |
Drugs and Companies using ROTIGOTINE ingredient
NCE-1 date: 10 May, 2011
Market Authorisation Date: 02 April, 2012
Treatment: NA
Dosage: FILM, EXTENDED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7335799 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Feb 21, 2025 |
New Indication(I-943) | Mar 22, 2027 |
New Indication(I-944) | Mar 22, 2027 |
Drugs and Companies using BEMPEDOIC ACID ingredient
NCE-1 date: 22 February, 2024
Market Authorisation Date: 21 February, 2020
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7335799 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Feb 26, 2023 |
New Chemical Entity Exclusivity(NCE) | Feb 21, 2025 |
New Indication(I-943) | Mar 22, 2027 |
New Indication(I-945) | Mar 22, 2027 |
Drugs and Companies using BEMPEDOIC ACID; EZETIMIBE ingredient
NCE-1 date: 22 February, 2024
Market Authorisation Date: 26 February, 2020
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9757552 | ORGANON | Applicator for inserting an implant |
Jul, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | May 31, 2014 |
Drugs and Companies using ETONOGESTREL ingredient
Market Authorisation Date: 17 July, 2006
Treatment: Prevention of pregnancy
Dosage: IMPLANT
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US11753301 | HOPE PHARMS | Sodium thiosulfate-containing pharmaceutical compositions |
Feb, 2030
(4 years from now) | |
US9345724 | HOPE PHARMS | Sodium thiosulfate-containing pharmaceutical compositions |
Jul, 2030
(5 years from now) | |
US9585912 | HOPE PHARMS | Sodium thiosulfate-containing pharmaceutical compositions |
Jul, 2030
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9687506 | HOPE PHARMS | Sodium nitrite-containing pharmaceutical compositions |
Feb, 2030
(4 years from now) | |
US10479686 | HOPE PHARMS | Sodium thiosulfate-containing pharmaceutical compositions |
Jul, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE) | Jan 14, 2018 |
Orphan Drug Exclusivity(ODE-5) | Jan 14, 2018 |
Drugs and Companies using SODIUM NITRITE; SODIUM THIOSULFATE ingredient
Market Authorisation Date: 14 January, 2011
Treatment: Sodium nitrite injection is indicated for sequential use with sodium thiosulfate for the treatment of acute cyanide poisoning; Sodium thiosulfate injection is administered by intravenous injection; Tr...
Dosage: SOLUTION, SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9974826 | FERRING PHARMS INC | Methods comprising desmopressin |
Apr, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Jun 21, 2021 |
Drugs and Companies using DESMOPRESSIN ACETATE ingredient
Market Authorisation Date: 21 June, 2018
Treatment: Treatment of nocturia due to nocturnal polyuria in adults, comprising monitoring a patient's serum sodium concentration
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11419914 | ACERUS PHARMS | Safe desmopressin administration |
Jun, 2030
(5 years from now) | |
US9539302 | ACERUS PHARMS | Safe desmopressin administration |
Jun, 2030
(5 years from now) | |
US12090190 | ACERUS PHARMS | Safe desmopressin administration |
Jun, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Mar 03, 2020 |
Drugs and Companies using DESMOPRESSIN ACETATE ingredient
Market Authorisation Date: 03 March, 2017
Treatment: Treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void by inducing an antidiuretic effect by intranasally administering a plume of droplets comprising ...
Dosage: SPRAY, METERED
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9657003 | BAYER HEALTHCARE | Androgen receptor modulating compounds |
Oct, 2030
(5 years from now) | |
US11046713 | BAYER HEALTHCARE | Androgen receptor modulating compounds |
Oct, 2030
(5 years from now) | |
US10711013 | BAYER HEALTHCARE | Androgen receptor modulating compounds |
Oct, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jul 30, 2024 |
New Indication(I-900) | Aug 05, 2025 |
Drugs and Companies using DAROLUTAMIDE ingredient
NCE-1 date: 31 July, 2023
Market Authorisation Date: 30 July, 2019
Treatment: Treatment of patients with non-metastatic castration resistant prostate cancer
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7601740 | ACADIA PHARMS INC | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Apr, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Apr 29, 2021 |
Drugs and Companies using PIMAVANSERIN TARTRATE ingredient
NCE-1 date: 29 April, 2020
Market Authorisation Date: 28 June, 2018
Treatment: NA
Dosage: CAPSULE; TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8314117 | PFIZER | CGRP receptor antagonists |
Mar, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-865) | May 27, 2024 |
New Chemical Entity Exclusivity(NCE) | Feb 27, 2025 |
Drugs and Companies using RIMEGEPANT SULFATE ingredient
NCE-1 date: 28 February, 2024
Market Authorisation Date: 27 February, 2020
Treatment: Preventive treatment of episodic migraine in adults
Dosage: TABLET, ORALLY DISINTEGRATING
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8383610 | PARATEK PHARMS INC | Salts and polymorphs of 9-(2,2-dimethylpropyl-aminomethyl) minocycline |
Sep, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Oct 02, 2023 |
Generating Antibiotic Incentives Now(GAIN) | Oct 02, 2028 |
Drugs and Companies using OMADACYCLINE TOSYLATE ingredient
NCE-1 date: 03 October, 2027
Market Authorisation Date: 02 October, 2018
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8486941 | GLAXOSMITHKLINE | Phenyl amino pyrimidine compounds and uses thereof |
Jan, 2030
(4 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Sep 15, 2028 |
Orphan Drug Exclusivity(ODE-441) | Sep 15, 2030 |
Drugs and Companies using MOMELOTINIB DIHYDROCHLORIDE ingredient
NCE-1 date: 16 September, 2027
Market Authorisation Date: 15 September, 2023
Treatment: For the treatment of intermediate or high-risk myelofibrosis
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10583130 | AMNEAL | Pharmaceutical formulations compromising nitrocatechol derivatives and methods of making thereof |
Mar, 2030
(5 years from now) | |
US10071085 | AMNEAL | Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof |
Mar, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Apr 24, 2025 |
Drugs and Companies using OPICAPONE ingredient
NCE-1 date: 24 April, 2024
Market Authorisation Date: 24 April, 2020
Treatment: Adjunctive treatment to levodopa/carbidopa in patients with parkinson’s disease experiencing off episodes
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8802644 | ALNYLAM PHARMS INC | Lipid formulation |
Oct, 2030
(5 years from now) | |
US8158601 | ALNYLAM PHARMS INC | Lipid formulation |
Nov, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Aug 10, 2023 |
Orphan Drug Exclusivity(ODE-197) | Aug 10, 2025 |
M(M-270) | Jan 13, 2026 |
Drugs and Companies using PATISIRAN SODIUM ingredient
NCE-1 date: 10 August, 2022
Market Authorisation Date: 10 August, 2018
Treatment: Treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8846628 | BRISTOL | Oral formulations of cytidine analogs and methods of use thereof |
Jun, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Sep 01, 2023 |
Orphan Drug Exclusivity(ODE-320) | Sep 01, 2027 |
Drugs and Companies using AZACITIDINE ingredient
Market Authorisation Date: 01 September, 2020
Treatment: Continued treatment of adults with acute myeloid leukemia who achieved first complete remission (cr) or cr with incomplete blood count recovery following intensive induction chemotherapy and are not a...
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8899229 | CURRAX | Powder delivery devices |
Aug, 2030
(5 years from now) | |
US9649456 | CURRAX | Nasal administration |
Oct, 2030
(5 years from now) | |
US8978647 | CURRAX | Nasal delivery |
Dec, 2030
(5 years from now) |
Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 27 January, 2016
Treatment: Acute treatment of migraine by delivering a powdered substance comprising sumatriptan via a breath-powered delivery device
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9682061 | MELINTA THERAP | Methods of treating bacterial infections using oritavancin |
Apr, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Aug 06, 2019 |
Generating Antibiotic Incentives Now(GAIN) | Aug 06, 2024 |
Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient
NCE-1 date: 07 August, 2023
Market Authorisation Date: 06 August, 2014
Treatment: Treatment of bacterial skin and skin structure infections
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8410169 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
Feb, 2030
(4 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosage Form(NDF) | Dec 20, 2016 |
New Dosing Schedule(D-156) | Jan 28, 2019 |
New Dosing Schedule(D-157) | Jan 28, 2019 |
Orphan Drug Exclusivity(ODE-308) | Dec 20, 2020 |
New Indication(I-820) | Oct 18, 2022 |
Orphan Drug Exclusivity(ODE-272) | Oct 18, 2026 |
Drugs and Companies using TREPROSTINIL DIOLAMINE ingredient
Market Authorisation Date: 20 December, 2013
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8507534 | VERTEX PHARMS INC | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
Sep, 2030
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8716338 | VERTEX PHARMS INC | Dosage units of 3-(6-(1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
Sep, 2030
(5 years from now) | |
US8993600 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Dec, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population(NPP) | Sep 02, 2025 |
Pediatric Exclusivity(PED) | Jan 02, 2023 |
New Chemical Entity Exclusivity(NCE) | Jul 02, 2020 |
M(M-218) | Jan 25, 2021 |
New Product(NP) | Aug 07, 2021 |
Orphan Drug Exclusivity(ODE-93) | Jul 02, 2022 |
Orphan Drug Exclusivity(ODE) | Sep 28, 2023 |
Orphan Drug Exclusivity(ODE-123) | Sep 28, 2023 |
Orphan Drug Exclusivity(ODE-195) | Aug 07, 2025 |
New Strength(NS) | Sep 02, 2025 |
Generating Antibiotic Incentives Now(GAIN) | Jan 02, 2028 |
Orphan Drug Exclusivity(ODE-408) | Sep 02, 2029 |
Drugs and Companies using IVACAFTOR; LUMACAFTOR ingredient
NCE-1 date: 02 January, 2022
Market Authorisation Date: 28 September, 2016
Treatment: Method of treating cystic fibrosis in a patient, the patient having the f508del mutation in cftr, using the dosage unit of claim 1 of u.s. patent no. 8,716,338
Dosage: TABLET; GRANULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8252331 | SUPERNUS PHARMS | Osmotic device containing amantadine and an osmotic salt |
Mar, 2030
(5 years from now) |
Drugs and Companies using AMANTADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 16 February, 2018
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8318817 | ALK ABELLO | Controlled release antimicrobial compositions and methods for the treatment of otic disorders |
Apr, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Dec 10, 2018 |
New Indication(I-770) | Mar 02, 2021 |
Drugs and Companies using CIPROFLOXACIN ingredient
Market Authorisation Date: 10 December, 2015
Treatment: Treatment of otic infection or inflammation
Dosage: INJECTABLE, SUSPENSION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8932610 | LABORATORIOS SALVAT | Aqueous clear solutions of fluocinolone acetonide for treatment of otic inflammation |
Mar, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Combination(NC) | Apr 29, 2019 |
Drugs and Companies using CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE ingredient
Market Authorisation Date: 29 April, 2016
Treatment: Treatment of acute otitis media
Dosage: SOLUTION/DROPS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9421333 | OTTER PHARMS | Hazardous agent injection system |
Mar, 2030
(5 years from now) | |
US8480631 | OTTER PHARMS | Hazardous agent injection system |
Mar, 2030
(5 years from now) | |
US8579865 | OTTER PHARMS | Hazardous agent injection system |
Mar, 2030
(5 years from now) | |
US8945063 | OTTER PHARMS | Hazardous agent injection system |
Mar, 2030
(5 years from now) | |
US11497753 | OTTER PHARMS | Hazardous agent injection system |
Mar, 2030
(5 years from now) |
Drugs and Companies using METHOTREXATE ingredient
Market Authorisation Date: 07 November, 2014
Treatment: Subcutaneous injection of methotrexate
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8894987 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Mar, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-153) | Apr 16, 2016 |
New Patient Population(NPP) | Aug 13, 2018 |
Drugs and Companies using OXYCODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 05 April, 2010
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8377880 | KAI PHARMS INC | Therapeutic agents for reducing parathyroid hormone levels |
Jul, 2030
(5 years from now) | |
US9701712 | KAI PHARMS INC | Therapeutic agents for reducing parathyroid hormone levels |
Jul, 2030
(5 years from now) | |
US9278995 | KAI PHARMS INC | Therapeutic agents for reducing parathyroid hormone levels |
Jul, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Feb 07, 2022 |
Drugs and Companies using ETELCALCETIDE ingredient
NCE-1 date: 07 February, 2021
Market Authorisation Date: 07 February, 2017
Treatment: A method of treating secondary hyperparathyroidism (shpt)
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8546450 | NUVO PHARMS INC | Treatment of pain with topical diclofenac compounds |
Aug, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosage Form(NDF) | Nov 04, 2012 |
New Product(NP) | Jan 16, 2017 |
Drugs and Companies using DICLOFENAC SODIUM ingredient
Market Authorisation Date: 04 November, 2009
Treatment: Use of topical diclofenac on the knee and a second topical agent selected from sunscreen and insect repellant
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8546450 | HORIZON | Treatment of pain with topical diclofenac compounds |
Aug, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosage Form(NDF) | Nov 04, 2012 |
New Product(NP) | Jan 16, 2017 |
Drugs and Companies using DICLOFENAC SODIUM ingredient
Market Authorisation Date: 16 January, 2014
Treatment: Use of topical diclofenac on the knee and a second topical agent selected from sunscreen and insect repellant
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8591938 | FRESENIUS MEDCL | Liquid compositions of calcium acetate |
Feb, 2030
(5 years from now) |
Drugs and Companies using CALCIUM ACETATE ingredient
Market Authorisation Date: 18 April, 2011
Treatment: Use of phoslyra for reduction of serum phosphorous in patients
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9993467 | BRISTOL | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
May, 2030
(5 years from now) | |
US10555939 | BRISTOL | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
May, 2030
(5 years from now) | |
US10555939 (Pediatric) | BRISTOL | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
Nov, 2030
(5 years from now) | |
US9993467 (Pediatric) | BRISTOL | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
Nov, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Feb 08, 2018 |
New Indication(I-707) | Apr 23, 2018 |
Orphan Drug Exclusivity(ODE) | Feb 08, 2020 |
Orphan Drug Exclusivity(ODE-43) | Feb 08, 2020 |
M(M-14) | Nov 20, 2023 |
Orphan Drug Exclusivity(ODE-296) | May 14, 2027 |
Orphan Drug Exclusivity(ODE-297) | May 14, 2027 |
Pediatric Exclusivity(PED) | Nov 14, 2027 |
Drugs and Companies using POMALIDOMIDE ingredient
NCE-1 date: 14 November, 2026
Market Authorisation Date: 08 February, 2013
Treatment: NA
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8778305 | PROGENICS PHARMS INC | PSMA-binding agents and uses thereof |
Sep, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | May 26, 2026 |
Drugs and Companies using PIFLUFOLASTAT F-18 ingredient
NCE-1 date: 26 May, 2025
Market Authorisation Date: 26 May, 2021
Treatment: Method of positron emission tomography (pet) in men with prostate cancer
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9744105 | JOURNEY | Topical glycopyrrolate formulations |
Jul, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Jun 28, 2021 |
Drugs and Companies using GLYCOPYRRONIUM TOSYLATE ingredient
Market Authorisation Date: 28 June, 2018
Treatment: Topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older
Dosage: CLOTH
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8188113 | DECIPHERA PHARMS | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
Jul, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | May 15, 2025 |
Orphan Drug Exclusivity(ODE-298) | May 15, 2027 |
Drugs and Companies using RIPRETINIB ingredient
NCE-1 date: 15 May, 2024
Market Authorisation Date: 15 May, 2020
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8545879 | TERSERA | Fast disintegrating compositions of meloxicam |
Aug, 2030
(5 years from now) |
Drugs and Companies using MELOXICAM ingredient
Market Authorisation Date: 19 October, 2018
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7919598 (Pediatric) | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jan 08, 2019 |
M(M-175) | Apr 05, 2019 |
New Combination(NC) | Feb 27, 2020 |
New Indication(I-804) | May 02, 2022 |
New Strength(NS) | May 02, 2022 |
Drugs and Companies using DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE ingredient
NCE-1 date: 08 January, 2018
Market Authorisation Date: 02 May, 2019
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7919598 (Pediatric) | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2030
(5 years from now) | |
US9616028 | ASTRAZENECA AB | Bilayer tablet formulations |
Nov, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | May 02, 2022 |
Market Authorisation Date: 02 May, 2019
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8821920 | AVERITAS | Therapeutic patch for transdermal delivery of capsaicin |
Mar, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Nov 16, 2014 |
Orphan Drug Exclusivity(ODE) | Nov 16, 2016 |
New Indication(I-838) | Jul 17, 2023 |
Drugs and Companies using CAPSAICIN ingredient
NCE-1 date: 16 November, 2013
Market Authorisation Date: 16 November, 2009
Treatment: NA
Dosage: PATCH
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9180090 | JDP | Non-sedating antihistamine injection formulations and methods of use thereof |
Feb, 2030
(4 years from now) | |
US9119771 | JDP | Non-sedating antihistamine injection formulations and methods of use thereof |
Feb, 2030
(4 years from now) | |
US8513259 | JDP | Non-sedating antihistamine injection formulations and methods of use thereof |
Feb, 2030
(4 years from now) | |
US8314083 | JDP | Non-sedating antihistamine injection formulations and methods of use thereof |
Feb, 2030
(5 years from now) | |
US8263581 | JDP | Non-sedating antihistamine injection formulations and methods of use thereof |
Feb, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Oct 04, 2022 |
Drugs and Companies using CETIRIZINE HYDROCHLORIDE ingredient
Market Authorisation Date: 04 October, 2019
Treatment: Treatment of acute urticaria; Method of increasing peak plasma or onset of plasma concentration by intravenous injection in individuals in need of treatment for acute urticaria; Method of treatment in...
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9326966 | HORIZON THERAP US | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Sep, 2030
(5 years from now) | |
US10183006 | HORIZON THERAP US | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Sep, 2030
(5 years from now) | |
US10183005 | HORIZON THERAP US | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Sep, 2030
(5 years from now) | |
US8642012 | HORIZON THERAP US | Methods of treatment using ammonia-scavenging drugs |
Sep, 2030
(5 years from now) | |
US10668040 | HORIZON THERAP US | Treatment of urea cycle disorders in neonates and infants |
Sep, 2030
(5 years from now) | |
US9561197 | HORIZON THERAP US | Methods of therapeutic monitoring of phenylacetic acid prodrugs |
Sep, 2030
(5 years from now) | |
US9999608 | HORIZON THERAP US | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Sep, 2030
(5 years from now) | |
US9254278 | HORIZON THERAP US | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Sep, 2030
(5 years from now) | |
US10045958 | HORIZON THERAP US | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Sep, 2030
(5 years from now) | |
US10183004 | HORIZON THERAP US | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Sep, 2030
(5 years from now) | |
US10183002 | HORIZON THERAP US | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Sep, 2030
(5 years from now) | |
US10183003 | HORIZON THERAP US | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Sep, 2030
(5 years from now) | |
US10045959 | HORIZON THERAP US | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Sep, 2030
(5 years from now) | |
US9962359 | HORIZON THERAP US | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Sep, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
NE(NE) | Feb 01, 2016 |
Orphan Drug Exclusivity(ODE) | Feb 01, 2020 |
Orphan Drug Exclusivity(ODE-42) | Feb 01, 2020 |
New Patient Population(NPP) | Dec 21, 2021 |
Orphan Drug Exclusivity(ODE-157) | Apr 28, 2024 |
Drugs and Companies using GLYCEROL PHENYLBUTYRATE ingredient
Market Authorisation Date: 01 February, 2013
Treatment: Treatment of a urea cycle disorder; Dosage adjustment of a nitrogen scavenging drug in the treatment of a urea cycle disorder
Dosage: LIQUID
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11801253 | EIRGEN | Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease |
Sep, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Jun 17, 2019 |
Drugs and Companies using CALCIFEDIOL ingredient
Market Authorisation Date: 17 June, 2016
Treatment: Treatment of secondary hyperparathyroidism with sustained release 25-hydroxyvitamin d in chronic kidney disease patients receiving cyp3a inhibitors
Dosage: CAPSULE, EXTENDED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8247425 | SALIX PHARMS | Peripheral opioid receptor antagonists and uses thereof |
Dec, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Apr 24, 2013 |
New Product(NP) | Jul 19, 2019 |
Drugs and Companies using METHYLNALTREXONE BROMIDE ingredient
NCE-1 date: 24 April, 2012
Market Authorisation Date: 27 September, 2010
Treatment: Treatment of opioid-induced constipation
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9095509 | GENZYME | Sachet formulation for amine polymers |
Dec, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosage Form(NDF) | Aug 12, 2012 |
New Patient Population(NPP) | Nov 25, 2019 |
Drugs and Companies using SEVELAMER CARBONATE ingredient
Market Authorisation Date: 18 February, 2009
Treatment: NA
Dosage: FOR SUSPENSION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US10174017 | ALCON LABS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(4 years from now) | |
US10654844 | ALCON LABS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(4 years from now) | |
US8394826 | ALCON LABS INC | Dual mechanism inhibitors for the treatment of disease |
Nov, 2030
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11028081 | ALCON LABS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(4 years from now) | |
US11618748 | ALCON LABS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(4 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Dec 18, 2022 |
Drugs and Companies using NETARSUDIL MESYLATE ingredient
NCE-1 date: 18 December, 2021
Market Authorisation Date: 18 December, 2017
Treatment: Reduction of elevated intraocular pressure
Dosage: SOLUTION/DROPS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US10174017 | ALCON LABS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(4 years from now) | |
US10654844 | ALCON LABS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(4 years from now) | |
US8394826 | ALCON LABS INC | Dual mechanism inhibitors for the treatment of disease |
Nov, 2030
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11028081 | ALCON LABS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(4 years from now) | |
US11618748 | ALCON LABS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(4 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Combination(NC) | Mar 12, 2022 |
New Chemical Entity Exclusivity(NCE) | Dec 18, 2022 |
Drugs and Companies using LATANOPROST; NETARSUDIL DIMESYLATE ingredient
NCE-1 date: 18 December, 2021
Market Authorisation Date: 12 March, 2019
Treatment: Reduction of elevated intraocular pressure
Dosage: SOLUTION/DROPS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8575146 | NOVARTIS | Pharmaceutical uses of staurosporine derivatives |
Dec, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Apr 28, 2022 |
Orphan Drug Exclusivity(ODE) | Apr 28, 2024 |
Orphan Drug Exclusivity(ODE-140) | Apr 28, 2024 |
Orphan Drug Exclusivity(ODE-141) | Apr 28, 2024 |
Drugs and Companies using MIDOSTAURIN ingredient
NCE-1 date: 28 April, 2021
Market Authorisation Date: 28 April, 2017
Treatment: Treatment of adult patients with aggressive systemic mastocytosis (asm), systemic mastocytosis with associated hematological neoplasm (sm-ahn), or mast cell leukemia (mcl)
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8617597 | BAYER HLTHCARE | Pharmaceutical composition containing a tetrahydrofolic acid |
Feb, 2030
(4 years from now) | |
US11617751 | BAYER HLTHCARE | Pharmaceutical composition containing a tetrahydrofolic acid |
Jul, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Dec 16, 2013 |
Drugs and Companies using DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM ingredient
Market Authorisation Date: 16 December, 2010
Treatment: Raise folate levels in women who choose to use an oral contraceptive as their method of contraception for the purpose of reducing the risk of a neural tube defect in a pregnancy
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8809615 | HISAMITSU PHARM CO | Adhesive preparation |
Jan, 2030
(4 years from now) |
Drugs and Companies using MENTHOL; METHYL SALICYLATE ingredient
Market Authorisation Date: 20 February, 2008
Treatment: NA
Dosage: PATCH
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10905694 | OTSUKA | Pharmaceutical solid preparation comprising benzazepines and production method thereof |
Apr, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | May 19, 2014 |
Drugs and Companies using TOLVAPTAN ingredient
NCE-1 date: 19 May, 2013
Market Authorisation Date: 19 May, 2009
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US10238668 | KOWA PHARMS | Co-crystals of tramadol and coxibis |
Apr, 2030
(5 years from now) | |
US8598152 | KOWA PHARMS | Co-crystals of tramadol and coxibs |
Apr, 2030
(5 years from now) | |
US9012440 | KOWA PHARMS | Co-crystals of tramadol and coxibs |
Apr, 2030
(5 years from now) | |
US10245276 | KOWA PHARMS | Co-crystals of tramadol and coxibs |
Apr, 2030
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11478488 | KOWA PHARMS | Co-crystals of tramadol and coxibs |
Apr, 2030
(5 years from now) | |
US10548909 | KOWA PHARMS | Co-crystals of tramadol and coxibs |
Apr, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Oct 15, 2024 |
Drugs and Companies using CELECOXIB; TRAMADOL HYDROCHLORIDE ingredient
Market Authorisation Date: 15 October, 2021
Treatment: A method for treatment of pain in adults using tramadol hydrochloride and celecoxib
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8080580 | MSD SUB MERCK | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Jul, 2030
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9308204 | MSD SUB MERCK | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Oct, 2030
(5 years from now) | |
US9439902 | MSD SUB MERCK | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Oct, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Dec 19, 2022 |
M(M-275) | Sep 17, 2024 |
Drugs and Companies using ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 19 December, 2021
Market Authorisation Date: 19 December, 2017
Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9364485 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(5 years from now) | |
US9655907 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(5 years from now) | |
US9439911 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(5 years from now) | |
US9775851 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(5 years from now) | |
US9433630 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(5 years from now) | |
US9877974 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(5 years from now) | |
US10179137 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosage Form(NDF) | Feb 05, 2019 |
Drugs and Companies using BETAMETHASONE DIPROPIONATE ingredient
Market Authorisation Date: 05 February, 2016
Treatment: Treatment of plaque psoriasis
Dosage: SPRAY
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8513299 | CURRAX | Methods of using low-dose doxepin for the improvement of sleep |
Sep, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Mar 17, 2013 |
Drugs and Companies using DOXEPIN HYDROCHLORIDE ingredient
Market Authorisation Date: 17 March, 2010
Treatment: Treatment of insomnia
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9421265 | ALCON LABS INC | Aqueous pharmaceutical compositions containing borate-polyol complexes |
Jun, 2030
(5 years from now) | |
US9044484 | ALCON LABS INC | Aqueous pharmaceutical compositions containing borate-polyol complexes |
Oct, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Combination(NC) | Apr 19, 2016 |
Drugs and Companies using BRIMONIDINE TARTRATE; BRINZOLAMIDE ingredient
Market Authorisation Date: 19 April, 2013
Treatment: NA
Dosage: SUSPENSION/DROPS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8592434 | LNHC | Mucoadhesive buccal tablets for the treatment of orofacial herpes |
Jun, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Apr 12, 2016 |
Drugs and Companies using ACYCLOVIR ingredient
Market Authorisation Date: 12 April, 2013
Treatment: Treatment of herpes labialis
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9624250 | CUBIST PHARMS LLC | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
Feb, 2030
(4 years from now) | |
US10442829 | CUBIST PHARMS LLC | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
Feb, 2030
(4 years from now) | |
US8426389 | CUBIST PHARMS LLC | Crystalline form of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
Dec, 2030
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9988406 | CUBIST PHARMS LLC | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
Feb, 2030
(4 years from now) | |
US10065947 | CUBIST PHARMS LLC | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
Feb, 2030
(4 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jun 20, 2019 |
New Patient Population(NPP) | Jun 19, 2023 |
Generating Antibiotic Incentives Now(GAIN) | Jun 20, 2024 |
Drugs and Companies using TEDIZOLID PHOSPHATE ingredient
NCE-1 date: 21 June, 2023
Market Authorisation Date: 20 June, 2014
Treatment: Method of treating acute bacterial skin and skin structure infections (absssi) caused by designated susceptible bacteria; Method of treating bacterial infections
Dosage: TABLET; POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9687506 | HOPE PHARMS | Sodium nitrite-containing pharmaceutical compositions |
Feb, 2030
(4 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE) | Jan 14, 2018 |
Orphan Drug Exclusivity(ODE-5) | Jan 14, 2018 |
Drugs and Companies using SODIUM NITRITE ingredient
Market Authorisation Date: 14 February, 2012
Treatment: Sodium nitrite injection is indicated for sequential use with sodium thiosulfate for the treatment of acute cyanide poisoning
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US11753301 | HOPE PHARMS | Sodium thiosulfate-containing pharmaceutical compositions |
Feb, 2030
(4 years from now) | |
US9345724 | HOPE PHARMS | Sodium thiosulfate-containing pharmaceutical compositions |
Jul, 2030
(5 years from now) | |
US9585912 | HOPE PHARMS | Sodium thiosulfate-containing pharmaceutical compositions |
Jul, 2030
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10479686 | HOPE PHARMS | Sodium thiosulfate-containing pharmaceutical compositions |
Jul, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE) | Jan 14, 2018 |
Orphan Drug Exclusivity(ODE-5) | Jan 14, 2018 |
Drugs and Companies using SODIUM THIOSULFATE ingredient
Market Authorisation Date: 14 February, 2012
Treatment: Sodium thiosulfate injection is administered by intravenous injection; Sodium thiosulfate injection is indicated for sequential use with sodium nitrite for the treatment of acute cyanide poisoning tha...
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9707176 | SANOFI-AVENTIS US | Pharmaceutical composition comprising a GLP-1 agonist and methionine |
Nov, 2030
(5 years from now) | |
US10029011 | SANOFI-AVENTIS US | Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine |
Nov, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Combination(NC) | Nov 21, 2019 |
New Chemical Entity Exclusivity(NCE) | Jul 27, 2021 |
Drugs and Companies using INSULIN GLARGINE; LIXISENATIDE ingredient
NCE-1 date: 27 July, 2020
Market Authorisation Date: 21 November, 2016
Treatment: NA
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9284342 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2030
(5 years from now) | |
US8618076 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Dec, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Dec 06, 2018 |
New Patient Population(NPP) | Apr 07, 2020 |
Orphan Drug Exclusivity(ODE) | Apr 07, 2024 |
ODE*(ODE*) | Aug 28, 2026 |
Orphan Drug Exclusivity(ODE-135) | Apr 07, 2024 |
Pediatric Exclusivity(PED) | Oct 07, 2024 |
Orphan Drug Exclusivity(ODE-258) | Aug 28, 2026 |
Drugs and Companies using SOFOSBUVIR ingredient
Market Authorisation Date: 28 August, 2019
Treatment: For the treatment of hepatitis c
Dosage: PELLETS; TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8361977 | BIOGEN IDEC | Compositions and methods for modulation of SMN2 splicing |
Dec, 2030
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9717750 | BIOGEN IDEC | Compositions and methods for modulation of SMN2 splicing in a subject |
Jun, 2030
(5 years from now) | |
US8980853 | BIOGEN IDEC | Compositions and methods for modulation of SMN2 splicing in a subject |
Nov, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-226) | May 14, 2021 |
New Chemical Entity Exclusivity(NCE) | Dec 23, 2021 |
Orphan Drug Exclusivity(ODE) | Dec 23, 2023 |
Orphan Drug Exclusivity(ODE-127) | Dec 23, 2023 |
Drugs and Companies using NUSINERSEN SODIUM ingredient
NCE-1 date: 23 December, 2020
Market Authorisation Date: 23 December, 2016
Treatment: Treatment of spinal muscular atrophy; Treatment of infantile-onset spinal muscular atrophy
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9010323 | BOEHRINGER INGELHEIM | Inhaler and sieve for an inhaler |
Apr, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-89) | Dec 17, 2012 |
Drugs and Companies using TIOTROPIUM BROMIDE ingredient
Market Authorisation Date: 30 January, 2004
Treatment: NA
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8733341 | BOEHRINGER INGELHEIM | Atomizer and method of atomizing fluid with a nozzle rinsing mechanism |
Oct, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Sep 15, 2018 |
New Patient Population(NPP) | Feb 15, 2020 |
Pediatric Exclusivity(PED) | Aug 15, 2020 |
Drugs and Companies using TIOTROPIUM BROMIDE ingredient
Market Authorisation Date: 15 September, 2015
Treatment: NA
Dosage: SPRAY, METERED
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8080580 | MSD SUB MERCK | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Jul, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Dec 19, 2022 |
M(M-275) | Sep 17, 2024 |
Drugs and Companies using ERTUGLIFLOZIN ingredient
NCE-1 date: 19 December, 2021
Market Authorisation Date: 19 December, 2017
Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8080580 | MSD SUB MERCK | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Jul, 2030
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9439901 | MSD SUB MERCK | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Oct, 2030
(5 years from now) | |
US9308204 | MSD SUB MERCK | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Oct, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Dec 19, 2022 |
M(M-275) | Sep 17, 2024 |
Drugs and Companies using ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE ingredient
NCE-1 date: 19 December, 2021
Market Authorisation Date: 19 December, 2017
Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8733341 | BOEHRINGER INGELHEIM | Atomizer and method of atomizing fluid with a nozzle rinsing mechanism |
Oct, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Combination(NC) | May 21, 2018 |
M(M-173) | Mar 18, 2019 |
New Chemical Entity Exclusivity(NCE) | Jul 31, 2019 |
M(M-233) | Oct 05, 2021 |
Drugs and Companies using OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE ingredient
NCE-1 date: 31 July, 2018
Market Authorisation Date: 21 May, 2015
Treatment: NA
Dosage: SPRAY, METERED
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8680124 | BAYER HLTHCARE | Treatment of cancers with acquired resistance to kit inhibitors |
Jun, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-667) | Feb 25, 2016 |
New Chemical Entity Exclusivity(NCE) | Sep 27, 2017 |
Orphan Drug Exclusivity(ODE) | Feb 25, 2020 |
Orphan Drug Exclusivity(ODE-44) | Feb 25, 2020 |
New Indication(I-744) | Apr 27, 2020 |
Orphan Drug Exclusivity(ODE-139) | Apr 27, 2024 |
Drugs and Companies using REGORAFENIB ingredient
NCE-1 date: 27 September, 2016
Market Authorisation Date: 27 September, 2012
Treatment: Treatment of patients with gastrointestinal stromal tumor (gist), including but not limited to patients previously treated with imatinib and patients with gist having resistance to a kit tyrosine kina...
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8148374 (Pediatric) | GILEAD SCIENCES INC | Modulators of pharmacokinetic properties of therapeutics |
Mar, 2030
(5 years from now) | |
US9891239 (Pediatric) | GILEAD SCIENCES INC | Modulators of pharmacokinetic properties of therapeutics |
Mar, 2030
(5 years from now) | |
US8633219 | GILEAD SCIENCES INC | Combination therapy |
Apr, 2030
(5 years from now) | |
US8633219 (Pediatric) | GILEAD SCIENCES INC | Combination therapy |
Oct, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Aug 27, 2015 |
New Chemical Entity Exclusivity(NCE) | Aug 27, 2017 |
New Indication(I-704) | Dec 17, 2017 |
New Patient Population(NPP) | Jan 27, 2020 |
NCE-1 date: 27 August, 2016
Market Authorisation Date: 27 August, 2012
Treatment: Treatment of hiv infection
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8733341 | BOEHRINGER INGELHEIM | Atomizer and method of atomizing fluid with a nozzle rinsing mechanism |
Oct, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jul 31, 2019 |
Drugs and Companies using OLODATEROL HYDROCHLORIDE ingredient
NCE-1 date: 31 July, 2018
Market Authorisation Date: 31 July, 2014
Treatment: NA
Dosage: SPRAY, METERED
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8475832 | INDIVIOR | Sublingual and buccal film compositions |
Mar, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosage Form(NDF) | Aug 30, 2013 |
Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 August, 2010
Treatment: This drug is administered by sublingual route to humans for maintenance treatment of opioid dependence
Dosage: FILM
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8486973 | BTCP PHARMA | Sublingual fentanyl spray |
Apr, 2030
(5 years from now) | |
US8486972 | BTCP PHARMA | Sublingual fentanyl spray |
Apr, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Jan 04, 2015 |
Drugs and Companies using FENTANYL ingredient
Market Authorisation Date: 04 January, 2012
Treatment: Treatment of pain
Dosage: SPRAY
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9415009 | ASTRAZENECA | Compositions, methods and systems for respiratory delivery of two or more active agents |
May, 2030
(5 years from now) | |
US10716753 | ASTRAZENECA | Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems |
May, 2030
(5 years from now) |
Drugs and Companies using BUDESONIDE; FORMOTEROL FUMARATE ingredient
Market Authorisation Date: 28 April, 2023
Treatment: Maintenance treatment of patients with chronic obstructive pulmonary disease (copd)
Dosage: AEROSOL, METERED
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US12115179 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Feb, 2030
(4 years from now) | |
US10610489 | BOEHRINGER INGELHEIM | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
Sep, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Aug 26, 2018 |
M(M-174) | Mar 18, 2019 |
New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
New Indication(I-739) | Dec 02, 2019 |
New Patient Population(NPP) | Jun 20, 2026 |
Pediatric Exclusivity(PED) | Dec 20, 2026 |
Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 26 August, 2015
Treatment: Treatment of type 2 diabetes mellitus by administration of empagliflozin, linagliptin and metformin
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US12115179 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Feb, 2030
(4 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
New Indication(I-739) | Dec 02, 2019 |
M(M-296) | Jun 20, 2026 |
Pediatric Exclusivity(PED) | Dec 20, 2026 |
Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 09 December, 2016
Treatment: Treatment of type 2 diabetes mellitus by administration of empagliflozin, linagliptin and metformin
Dosage: TABLET, EXTENDED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7994185 | NOVARTIS | Benzene sulfonamide thiazole and oxazole compounds |
Jan, 2030
(4 years from now) | |
US8415345 | NOVARTIS | Benzene sulfonamide thiazole and oxazole compounds |
Jan, 2030
(4 years from now) | |
US8703781 | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors |
Oct, 2030
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8415345 (Pediatric) | NOVARTIS | Benzene sulfonamide thiazole and oxazole compounds |
Jul, 2030
(5 years from now) | |
US7994185 (Pediatric) | NOVARTIS | Benzene sulfonamide thiazole and oxazole compounds |
Jul, 2030
(5 years from now) | |
US8952018 | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors |
Oct, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-678) | Jan 08, 2017 |
New Chemical Entity Exclusivity(NCE) | May 29, 2018 |
M(M-170) | Nov 20, 2018 |
Orphan Drug Exclusivity(ODE) | May 29, 2020 |
Orphan Drug Exclusivity(ODE-47) | May 29, 2020 |
New Indication(I-745) | Jun 22, 2020 |
Orphan Drug Exclusivity(ODE-58) | Jan 09, 2021 |
New Indication(I-778) | Apr 30, 2021 |
New Indication(I-781) | May 04, 2021 |
M(M-246) | Oct 06, 2022 |
Orphan Drug Exclusivity(ODE-147) | Jun 22, 2024 |
Orphan Drug Exclusivity(ODE-182) | Apr 30, 2025 |
Orphan Drug Exclusivity(ODE-183) | May 04, 2025 |
New Indication(I-894) | Jun 22, 2025 |
Pediatric Exclusivity(PED) | Sep 16, 2026 |
New Indication(I-908) | Mar 16, 2026 |
New Product(NP) | Mar 16, 2026 |
Orphan Drug Exclusivity(ODE-428) | Mar 16, 2030 |
Drugs and Companies using DABRAFENIB MESYLATE ingredient
Market Authorisation Date: 16 March, 2023
Treatment: Tafinlar(r) is indicated, in combination with trametinib, for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with braf v600e mutation as detected by an fda-approved test....
Dosage: TABLET, FOR SUSPENSION; CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8263122 | RIGEL PHARMS | Wet granulation using a water sequestering agent |
Nov, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Apr 17, 2023 |
Orphan Drug Exclusivity(ODE-174) | Apr 17, 2025 |
Drugs and Companies using FOSTAMATINIB DISODIUM ingredient
NCE-1 date: 17 April, 2022
Market Authorisation Date: 17 April, 2018
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9006387 | ABBVIE | Anti-viral compounds |
Jun, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-743) | Jul 24, 2018 |
New Product(NP) | Jul 24, 2018 |
New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
Drugs and Companies using OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 24 July, 2015
Treatment: Treatment of hcv infection using ombitasvir
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9629861 | ABBVIE | Compositions and methods for treating bacterial infections using ceftaroline |
Sep, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Oct 29, 2015 |
New Patient Population(NPP) | Sep 13, 2022 |
Drugs and Companies using CEFTAROLINE FOSAMIL ingredient
NCE-1 date: 29 October, 2014
Market Authorisation Date: 29 October, 2010
Treatment: NA
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8580781 | EMD SERONO INC | Pyridazinone derivatives |
Mar, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Feb 03, 2026 |
Orphan Drug Exclusivity(ODE-325) | Feb 03, 2028 |
Drugs and Companies using TEPOTINIB HYDROCHLORIDE ingredient
NCE-1 date: 03 February, 2025
Market Authorisation Date: 03 February, 2021
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10610125 | SERVIER | Methods and compositions for cell-proliferation-related disorders |
Jun, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-816) | May 02, 2022 |
New Chemical Entity Exclusivity(NCE) | Jul 20, 2023 |
New Indication(I-875) | Aug 25, 2024 |
New Indication(I-893) | May 25, 2025 |
Orphan Drug Exclusivity(ODE-203) | Jul 20, 2025 |
Orphan Drug Exclusivity(ODE-242) | May 02, 2026 |
New Indication(I-924) | Oct 24, 2026 |
Orphan Drug Exclusivity(ODE-368) | Aug 25, 2028 |
Orphan Drug Exclusivity(ODE-447) | Oct 24, 2030 |
Drugs and Companies using IVOSIDENIB ingredient
NCE-1 date: 20 July, 2022
Market Authorisation Date: 20 July, 2018
Treatment: A method for treating newly diagnosed aml with ivosidenib and azacitidine wherein the aml has an idh1 mutation capable of converting alpha-ketoglutarate to 2-hydroxyglutarate (2hg)
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9242986 (Pediatric) | VIIV HLTHCARE | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
Jun, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-166) | Jul 30, 2018 |
New Chemical Entity Exclusivity(NCE) | Aug 12, 2018 |
New Indication(I-758) | Nov 21, 2020 |
Drugs and Companies using DOLUTEGRAVIR SODIUM ingredient
NCE-1 date: 12 August, 2017
Market Authorisation Date: 09 June, 2016
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9242986 (Pediatric) | VIIV HLTHCARE | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
Jun, 2030
(5 years from now) |
Drugs and Companies using DOLUTEGRAVIR SODIUM ingredient
Market Authorisation Date: 12 June, 2020
Treatment: NA
Dosage: TABLET, FOR SUSPENSION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9089471 | GENUS | Formulation of indomethacin |
Apr, 2030
(5 years from now) | |
US8734847 | GENUS | Formulation of indomethacin |
Apr, 2030
(5 years from now) | |
US8992982 | GENUS | Formulation of indomethacin |
Apr, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Feb 24, 2017 |
Drugs and Companies using INDOMETHACIN ingredient
Market Authorisation Date: 24 February, 2014
Treatment: Treatment of pain
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10226473 | VERITY | High-strength testosterone undecanoate compositions |
Nov, 2030
(5 years from now) | |
US9943527 | VERITY | High-strength testosterone undecanoate compositions |
Nov, 2030
(5 years from now) | |
US11364249 | VERITY | High-strength testosterone undecanoate compositions |
Nov, 2030
(5 years from now) | |
US11433083 | VERITY | High-strength testosterone undecanoate compositions |
Nov, 2030
(5 years from now) | |
US10716794 | VERITY | High-strength testosterone undecanoate compositions |
Nov, 2030
(5 years from now) | |
US9949985 | VERITY | High-strength testosterone undecanoate compositions |
Nov, 2030
(5 years from now) | |
US11311555 | VERITY | High-strength testosterone undecanoate compositions |
Nov, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Mar 28, 2025 |
Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient
Market Authorisation Date: 28 March, 2022
Treatment: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; Primary hypogonadism (congenital or acquired); Hypogonadotropic hypog...
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10207066 | MYLAN SPECIALITY LP | Aerosolization apparatus with capsule puncture alignment guide |
Nov, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Mar 22, 2016 |
Drugs and Companies using TOBRAMYCIN ingredient
Market Authorisation Date: 22 March, 2013
Treatment: Treatment of cystic fibrosis patients with pseudomonas aeruginosa
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9610280 | TONIX MEDS | Formulations comprising triptan compounds |
Jun, 2030
(5 years from now) | |
US12090139 | TONIX MEDS | Formulations comprising triptan compounds |
Jun, 2030
(5 years from now) | |
US9974770 | TONIX MEDS | Formulations comprising triptan compounds |
Jun, 2030
(5 years from now) | |
US10603305 | TONIX MEDS | Formulations comprising triptan compounds |
Jun, 2030
(5 years from now) | |
US11337962 | TONIX MEDS | Formulations comprising triptan compounds |
Jun, 2030
(5 years from now) |
Drugs and Companies using SUMATRIPTAN ingredient
Market Authorisation Date: 25 January, 2019
Treatment: Acute treatment of migraine
Dosage: SPRAY
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9486526 (Pediatric) | BOEHRINGER INGELHEIM | Treatment for diabetes in patients inappropriate for metformin therapy |
Feb, 2030
(4 years from now) | |
US10034877 (Pediatric) | BOEHRINGER INGELHEIM | Treatment for diabetes in patients inappropriate for metformin therapy |
Feb, 2030
(4 years from now) | |
US11911388 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug |
Apr, 2030
(5 years from now) | |
US8846695 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
Jun, 2030
(5 years from now) | |
US8846695 (Pediatric) | BOEHRINGER INGELHEIM | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
Dec, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-118) | Aug 13, 2015 |
M(M-121) | Aug 13, 2015 |
New Chemical Entity Exclusivity(NCE) | May 02, 2016 |
M(M-258) | Jul 03, 2022 |
M(M-252) | Mar 30, 2023 |
M(M-295) | Jun 20, 2026 |
Pediatric Exclusivity(PED) | Dec 20, 2026 |
Drugs and Companies using LINAGLIPTIN ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 02 May, 2011
Treatment: Linagliptin (5 mg daily dose) and metformin (with or without insulin) for treating type 2 diabetes patients with renal impairment and insufficient glycemic control despite previous treatment with metf...
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8344006 (Pediatric) | CEPHALON | Liquid formulations of bendamustine |
Mar, 2030
(5 years from now) | |
US8436190 | CEPHALON | Bendamustine pharmaceutical compositions |
Oct, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-580) | Oct 31, 2011 |
New Chemical Entity Exclusivity(NCE) | Mar 20, 2013 |
Pediatric Exclusivity(PED) | May 01, 2016 |
Orphan Drug Exclusivity(ODE) | Oct 31, 2015 |
ODE*(ODE*) | Dec 07, 2022 |
Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient
NCE-1 date: 02 May, 2015
Market Authorisation Date: 01 May, 2009
Treatment: NA
Dosage: SOLUTION; POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8534281 | GLAXOSMITHKLINE | Manifold for use in medicament dispenser |
Mar, 2030
(5 years from now) | |
US8534281 (Pediatric) | GLAXOSMITHKLINE | Manifold for use in medicament dispenser |
Sep, 2030
(5 years from now) | |
US8746242 | GLAXOSMITHKLINE | Medicament dispenser |
Oct, 2030
(5 years from now) | |
US9750726 | GLAXOSMITHKLINE | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist |
Nov, 2030
(5 years from now) | |
US11090294 | GLAXOSMITHKLINE | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist |
Nov, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Dec 18, 2018 |
New Indication(I-775) | Apr 24, 2021 |
New Indication(I-843) | Sep 09, 2023 |
New Strength(NS) | Sep 09, 2023 |
NCE-1 date: 18 December, 2017
Market Authorisation Date: 18 September, 2017
Treatment: Maintenance treatment of chronic obstructive pulmonary disease (copd) comprising the once per day administration of trelegy ellipta, 100 mcg fluticasone furoate/62.5 mcg umeclidinium/25 mcg vilanterol
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US12115179 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Feb, 2030
(4 years from now) | |
US8551957 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate |
Apr, 2030
(5 years from now) | |
US9155705 | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
May, 2030
(5 years from now) | |
US10406172 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Jun, 2030
(5 years from now) |
Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 27 January, 2020
Treatment: Treatment of type 2 diabetes mellitus by administration of empagliflozin, linagliptin and metformin; Method of treating a type 2 diabetes mellitus patient with insufficient glycemic control despite th...
Dosage: TABLET, EXTENDED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9242986 (Pediatric) | VIIV HLTHCARE | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
Jun, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosing Schedule(D-147) | Mar 23, 2018 |
New Chemical Entity Exclusivity(NCE) | Aug 12, 2018 |
M(M-294) | Jun 15, 2026 |
Pediatric Exclusivity(PED) | Dec 15, 2026 |
Drugs and Companies using ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient
NCE-1 date: 15 December, 2025
Market Authorisation Date: 22 August, 2014
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9242986 (Pediatric) | VIIV HLTHCARE | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
Jun, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population(NPP) | Jun 15, 2026 |
Pediatric Exclusivity(PED) | Dec 15, 2026 |
Drugs and Companies using ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient
Market Authorisation Date: 30 March, 2022
Treatment: NA
Dosage: TABLET, FOR SUSPENSION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8101623 | ASTRAZENECA | Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor |
Mar, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Nov 16, 2028 |
Drugs and Companies using CAPIVASERTIB ingredient
NCE-1 date: 17 November, 2027
Market Authorisation Date: 16 November, 2023
Treatment: Treatment with fulvestrant of hr-pos. her2-neg. locally advanced or metastatic breast cancer with pik3ca/akt1/pten-alteration(s) following progression on endocrine therapy in the metastatic setting or...
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US12070629 | GALDERMA LABS LP | Core stabilized microcapsules, method of their preparation and uses thereof |
Dec, 2030
(5 years from now) | |
US11071878 | GALDERMA LABS LP | Core stabilized microcapsules, method of their preparation and uses thereof |
Dec, 2030
(5 years from now) | |
US10653899 | GALDERMA LABS LP | Core stabilized microcapsules, method of their preparation and uses thereof |
Dec, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Combination(NC) | Jul 26, 2024 |
Drugs and Companies using BENZOYL PEROXIDE; TRETINOIN ingredient
Market Authorisation Date: 26 July, 2021
Treatment: Topical treatment of acne; Topical treatment of acne vulgaris in adults and pediatric patients 9 years of age and older
Dosage: CREAM
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8148374 (Pediatric) | GILEAD SCIENCES INC | Modulators of pharmacokinetic properties of therapeutics |
Mar, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Aug 27, 2017 |
New Product(NP) | Sep 24, 2017 |
New Patient Population(NPP) | Aug 22, 2022 |
Orphan Drug Exclusivity(ODE-260) | Aug 22, 2026 |
Drugs and Companies using COBICISTAT ingredient
NCE-1 date: 27 August, 2016
Market Authorisation Date: 24 September, 2014
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8372995 | PF PRISM CV | Crystalline solid forms of tigecycline and methods of preparing same |
Oct, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-586) | Mar 20, 2012 |
New Indication(I-587) | Mar 20, 2012 |
New Indication(I-588) | Mar 20, 2012 |
Drugs and Companies using TIGECYCLINE ingredient
Market Authorisation Date: 15 June, 2005
Treatment: NA
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10772883 | UNITED THERAP | Diketopiperazine microparticles with defined specific surface areas |
Jun, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | May 23, 2025 |
Drugs and Companies using TREPROSTINIL ingredient
Market Authorisation Date: 23 May, 2022
Treatment: NA
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8791122 | ACTELION | Form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide and method for producing the same |
Aug, 2030
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9284280 | ACTELION | Use of form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide |
Jun, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Dec 21, 2020 |
Orphan Drug Exclusivity(ODE) | Dec 21, 2022 |
Orphan Drug Exclusivity(ODE-106) | Dec 21, 2022 |
Drugs and Companies using SELEXIPAG ingredient
Market Authorisation Date: 29 July, 2021
Treatment: Method of treating pulmonary arterial hypertension comprising administering a crystalline form of selexipag
Dosage: POWDER; TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8836218 | DAIICHI SANKYO INC | Methods of treatment using combination therapy |
Mar, 2030
(5 years from now) | |
US9555040 | DAIICHI SANKYO INC | Methods of treating proliferative diseases |
May, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jul 20, 2028 |
Orphan Drug Exclusivity(ODE-437) | Jul 20, 2030 |
Drugs and Companies using QUIZARTINIB DIHYDROCHLORIDE ingredient
NCE-1 date: 21 July, 2027
Market Authorisation Date: 20 July, 2023
Treatment: Combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for adult patients with newly diagno...
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8318715 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(4 years from now) | |
US8314086 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(4 years from now) | |
US8680144 | AMARIN PHARMS | Methods of treating mixed dyslipidemia |
Feb, 2030
(4 years from now) | |
US8415335 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(4 years from now) | |
US8399446 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(4 years from now) | |
US8518929 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(4 years from now) | |
US8293727 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(4 years from now) | |
US8524698 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(4 years from now) | |
US8357677 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(4 years from now) | |
US8293728 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(4 years from now) | |
US8546372 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(4 years from now) | |
US8377920 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(4 years from now) | |
US8367652 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(4 years from now) | |
US8431560 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(4 years from now) | |
US8440650 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(4 years from now) | |
US8426399 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(4 years from now) | |
US11717504 | AMARIN PHARMS | Methods of reducing the risk of cardiovascular events in a subject |
Apr, 2030
(5 years from now) | |
US10010517 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
US8691871 | AMARIN PHARMS | Methods of treating mixed dyslipidemia |
Apr, 2030
(5 years from now) | |
US8709475 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
US8703185 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
US8623406 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
US8642077 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
US8618166 | AMARIN PHARMS | Methods of treating mixed dyslipidemia |
Apr, 2030
(5 years from now) | |
US8617593 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
US8454994 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
US11103477 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
US8445013 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
US8551521 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
US8617594 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
US8445003 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
US11154526 | AMARIN PHARMS | Methods of treating mixed dyslipidemia |
Apr, 2030
(5 years from now) | |
US11213504 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
US8501225 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
US8563608 | AMARIN PHARMS | Methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
Apr, 2030
(5 years from now) | |
US10881632 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
US8298554 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
US10265287 | AMARIN PHARMS | Methods of reducing triglycerides and LDL-C |
Apr, 2030
(5 years from now) | |
US10842766 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
US10792267 | AMARIN PHARMS | Methods of treating mixed dyslipidemia |
Apr, 2030
(5 years from now) | |
US8669245 | AMARIN PHARMS | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
Jun, 2030
(5 years from now) | |
US8710041 | AMARIN PHARMS | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy |
Jun, 2030
(5 years from now) | |
US10842768 | AMARIN PHARMS | Compositions and methods for lowering triglycerides |
Jun, 2030
(5 years from now) | |
US8410086 | AMARIN PHARMS | Compositions and methods for lowering triglycerides |
Jun, 2030
(5 years from now) | |
US8455472 | AMARIN PHARMS | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
Jun, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Jul 26, 2015 |
New Chemical Entity Exclusivity(NCE) | Jul 26, 2017 |
New Indication(I-819) | Dec 13, 2022 |
Drugs and Companies using ICOSAPENT ETHYL ingredient
NCE-1 date: 26 July, 2016
Market Authorisation Date: 26 July, 2012
Treatment: Method of reducing tg levels in patient suffering from severe hypertriglyceridemia; Use of vascepa to treat mixed hypertriglyceridemia in an adult patient with elevated triglyceride (tg) levels (>= 15...
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8008264 (Pediatric) | GILEAD SCIENCES INC | 1′-substituted carba-nucleoside analogs for antiviral treatment |
Mar, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosing Schedule(D-183) | Jan 21, 2025 |
New Patient Population(NPP) | Apr 25, 2025 |
New Chemical Entity Exclusivity(NCE) | Oct 22, 2025 |
M(M-301) | Jul 13, 2026 |
Pediatric Exclusivity(PED) | Jan 13, 2027 |
Drugs and Companies using REMDESIVIR ingredient
NCE-1 date: 13 January, 2026
Market Authorisation Date: 22 October, 2020
Treatment: NA
Dosage: POWDER; SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9561251 | VIFOR FRESENIUS | Pharmaceutical compositions |
Jan, 2030
(4 years from now) | |
US9561251 (Pediatric) | VIFOR FRESENIUS | Pharmaceutical compositions |
Jul, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Nov 27, 2016 |
New Patient Population(NPP) | Jul 01, 2027 |
Pediatric Exclusivity(PED) | Jan 01, 2028 |
Drugs and Companies using FERRIC OXYHYDROXIDE ingredient
Market Authorisation Date: 27 November, 2013
Treatment: Control of phosphorous levels in patients
Dosage: TABLET, CHEWABLE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8580841 | PFIZER | Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
Mar, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Oct 12, 2028 |
Drugs and Companies using ETRASIMOD ARGININE ingredient
NCE-1 date: 13 October, 2027
Market Authorisation Date: 12 October, 2023
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8337824 | VIFOR PHARMA | Linear polyol stabilized polyfluoroacrylate compositions |
May, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Oct 21, 2020 |
New Patient Population(NPP) | Oct 02, 2026 |
New Strength(NS) | Oct 02, 2026 |
Drugs and Companies using PATIROMER SORBITEX CALCIUM ingredient
NCE-1 date: 22 October, 2019
Market Authorisation Date: 02 October, 2023
Treatment: Treatment of hyperkalemia
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9174982 | ABBVIE | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
May, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Apr 11, 2021 |
New Indication(I-782) | Jun 08, 2021 |
M(M-228) | Jun 08, 2021 |
New Indication(I-789) | Nov 21, 2021 |
New Indication(I-795) | May 15, 2022 |
Orphan Drug Exclusivity(ODE) | Apr 11, 2023 |
Orphan Drug Exclusivity(ODE-114) | Apr 11, 2023 |
M(M-265) | Oct 16, 2023 |
Orphan Drug Exclusivity(ODE-185) | Jun 08, 2025 |
Orphan Drug Exclusivity(ODE-211) | Nov 21, 2025 |
Orphan Drug Exclusivity(ODE-239) | May 15, 2026 |
Drugs and Companies using VENETOCLAX ingredient
NCE-1 date: 11 April, 2020
Market Authorisation Date: 11 April, 2016
Treatment: Treatment in combination with azacitidine or decitabine or low-dose cytarabine of newly-diagnosed acute myeloid leukemia (aml) in adults who are age 75 years or older, or who have comorbidities that p...
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8614178 | HARROW EYE | Pharmaceutical composition for treatment of dry eye syndrome |
Dec, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | May 30, 2026 |
Drugs and Companies using CYCLOSPORINE ingredient
Market Authorisation Date: 30 May, 2023
Treatment: NA
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9006387 | ABBVIE | Anti-viral compounds |
Jun, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosing Schedule(D-163) | Apr 22, 2019 |
New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 19 December, 2014
Treatment: Treatment of hcv infection using ombitasvir
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9006387 | ABBVIE | Anti-viral compounds |
Jun, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 22 July, 2016
Treatment: Treatment of hcv infection using ombitasvir
Dosage: TABLET, EXTENDED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8980873 | SOBI | 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt |
Mar, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Feb 28, 2027 |
Orphan Drug Exclusivity(ODE-397) | Feb 28, 2029 |
Drugs and Companies using PACRITINIB CITRATE ingredient
NCE-1 date: 28 February, 2026
Market Authorisation Date: 28 February, 2022
Treatment: Use of pacritinib for inhibiting janus associated kinase 2(jak2)
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9186411 | PHATHOM | Pharmaceutical composition |
Aug, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Nov 01, 2026 |
New Chemical Entity Exclusivity(NCE) | May 03, 2027 |
New Indication(I-948) | Jul 17, 2027 |
Drugs and Companies using VONOPRAZAN FUMARATE ingredient
NCE-1 date: 03 May, 2026
Market Authorisation Date: 01 November, 2023
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9186411 | PHATHOM | Pharmaceutical composition |
Aug, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | May 03, 2027 |
Generating Antibiotic Incentives Now(GAIN) | May 03, 2032 |
Drugs and Companies using AMOXICILLIN; VONOPRAZAN FUMARATE ingredient
NCE-1 date: 04 May, 2031
Market Authorisation Date: 03 May, 2022
Treatment: NA
Dosage: CAPSULE, TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9186411 | PHATHOM | Pharmaceutical composition |
Aug, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | May 03, 2027 |
Generating Antibiotic Incentives Now(GAIN) | May 03, 2032 |
Drugs and Companies using AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE ingredient
NCE-1 date: 04 May, 2031
Market Authorisation Date: 03 May, 2022
Treatment: NA
Dosage: CAPSULE, TABLET, TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9284342 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2030
(5 years from now) | |
US8618076 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Dec, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jul 18, 2022 |
Drugs and Companies using SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR ingredient
NCE-1 date: 18 July, 2021
Market Authorisation Date: 18 July, 2017
Treatment: Treatment of adult patients with chronic hcv infection who have genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an hcv regimen containing an ns5a inhibitor
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8198242 | BIOMARIN PHARM | Variants of C-type natriuretic peptide |
Jun, 2030
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
USRE48267 | BIOMARIN PHARM | Variants of C-type natriuretic peptide |
May, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population(NPP) | Oct 20, 2026 |
New Chemical Entity Exclusivity(NCE) | Nov 19, 2026 |
Orphan Drug Exclusivity(ODE-387) | Nov 19, 2028 |
Orphan Drug Exclusivity(ODE-449) | Oct 20, 2030 |
Drugs and Companies using VOSORITIDE ingredient
NCE-1 date: 19 November, 2025
Market Authorisation Date: 19 November, 2021
Treatment: Use to increase linear growth in pediatric patients with achondroplasia with open epiphyses
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8207197 | HARMONY | Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy] propyl] -piperidine |
Mar, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-846) | Oct 13, 2023 |
New Chemical Entity Exclusivity(NCE) | Aug 14, 2024 |
Orphan Drug Exclusivity(ODE-255) | Aug 14, 2026 |
New Patient Population(NPP) | Jun 21, 2027 |
Orphan Drug Exclusivity(ODE-331) | Oct 13, 2027 |
Orphan Drug Exclusivity(ODE-489) | Jun 21, 2031 |
Drugs and Companies using PITOLISANT HYDROCHLORIDE ingredient
NCE-1 date: 15 August, 2023
Market Authorisation Date: 14 August, 2019
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8785427 | SUN PHARM | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
Jul, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Aug 26, 2025 |
Drugs and Companies using CLASCOTERONE ingredient
NCE-1 date: 26 August, 2024
Market Authorisation Date: 26 August, 2020
Treatment: NA
Dosage: CREAM
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8597681 | MALLINCKRODT INC | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
Dec, 2030
(5 years from now) | |
US8980319 | MALLINCKRODT INC | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
Dec, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Mar 11, 2017 |
Drugs and Companies using ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 11 March, 2014
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8383659 | TARSUS | Isoxazoline derivatives as pesticides |
Jan, 2030
(4 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jul 24, 2028 |
Drugs and Companies using LOTILANER ingredient
NCE-1 date: 25 July, 2027
Market Authorisation Date: 24 July, 2023
Treatment: NA
Dosage: SOLUTION/DROPS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8906887 | TETRAPHASE PHARMS | C7-fluoro substituted tetracycline compounds |
Dec, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Aug 27, 2023 |
Generating Antibiotic Incentives Now(GAIN) | Aug 27, 2028 |
Drugs and Companies using ERAVACYCLINE DIHYDROCHLORIDE ingredient
NCE-1 date: 28 August, 2027
Market Authorisation Date: 27 August, 2018
Treatment: NA
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8978647 | OPTINOSE US INC | Nasal delivery |
Dec, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Sep 18, 2020 |
New Indication(I-940) | Mar 15, 2027 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 18 September, 2017
Treatment: NA
Dosage: SPRAY, METERED
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8685934 | ASTRAZENECA AB | Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof |
May, 2030
(5 years from now) | |
US7919598 (Pediatric) | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2030
(5 years from now) | |
US9616028 | ASTRAZENECA AB | Bilayer tablet formulations |
Nov, 2030
(5 years from now) | |
US8685934 (Pediatric) | ASTRAZENECA AB | Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof |
Nov, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jan 08, 2019 |
M(M-238) | Feb 22, 2022 |
New Indication(I-841) | Oct 18, 2022 |
New Patient Population(NPP) | Jun 12, 2027 |
Pediatric Exclusivity(PED) | Dec 12, 2027 |
Drugs and Companies using DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 12 December, 2026
Market Authorisation Date: 28 July, 2017
Treatment: Treatment of type 2 diabetes mellitus in a patient, wherein glycemic control (hba1c < 7.0%) is not achievable using one or more of insulin, metformin, pioglitazone, or rosiglitazone
Dosage: TABLET, EXTENDED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9890141 | BAUSCH AND LOMB INC | Crystalline pharmaceutical and methods of preparation and use thereof |
Oct, 2030
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9353088 | BAUSCH AND LOMB INC | Crystalline pharmaceutical and methods of preparation and use thereof |
Oct, 2030
(5 years from now) | |
US8927574 | BAUSCH AND LOMB INC | Crystalline pharmaceutical and methods of preparation and use thereof |
Nov, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jul 11, 2021 |
Drugs and Companies using LIFITEGRAST ingredient
NCE-1 date: 11 July, 2020
Market Authorisation Date: 11 July, 2016
Treatment: NA
Dosage: SOLUTION/DROPS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9815835 | GENENTECH INC | Substituted polycyclic carbamolypyridone derivative |
Jun, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-811) | Oct 16, 2022 |
New Chemical Entity Exclusivity(NCE) | Oct 24, 2023 |
Drugs and Companies using BALOXAVIR MARBOXIL ingredient
NCE-1 date: 24 October, 2022
Market Authorisation Date: 24 October, 2018
Treatment: NA
Dosage: TABLET; FOR SUSPENSION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9487491 | ASTELLAS | Diamino heterocyclic carboxamide compound |
Jul, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Nov 28, 2023 |
Orphan Drug Exclusivity(ODE-222) | Nov 28, 2025 |
Drugs and Companies using GILTERITINIB FUMARATE ingredient
NCE-1 date: 28 November, 2022
Market Authorisation Date: 28 November, 2018
Treatment: Treatment of acute myeloid leukemia (aml)
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10668060 | COLLEGIUM PHARM INC | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
Dec, 2030
(5 years from now) | |
US10004729 | COLLEGIUM PHARM INC | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
Dec, 2030
(5 years from now) | |
US9682075 | COLLEGIUM PHARM INC | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
Dec, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Apr 26, 2019 |
Drugs and Companies using OXYCODONE ingredient
Market Authorisation Date: 26 April, 2016
Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate
Dosage: CAPSULE, EXTENDED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9119859 | FONSECA BIOSCIENCES | Methods for treating otic infections |
Jul, 2030
(5 years from now) | |
US9993483 | FONSECA BIOSCIENCES | Compositions and methods for treating ophthalmic, octic, or nasal infections |
Jul, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Dec 17, 2019 |
Pediatric Exclusivity(PED) | Jun 17, 2020 |
Drugs and Companies using FINAFLOXACIN ingredient
NCE-1 date: 18 June, 2019
Market Authorisation Date: 17 December, 2014
Treatment: Treatment of acute otitis externa
Dosage: SUSPENSION/DROPS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11497753 | ANTARES PHARMA INC | Hazardous agent injection system |
Mar, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Sep 28, 2021 |
Drugs and Companies using TESTOSTERONE ENANTHATE ingredient
Market Authorisation Date: 28 September, 2018
Treatment: NA
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US11858898 | MYLAN IRELAND LTD | Crystalline freebase forms of a biphenyl compound |
Jul, 2030
(5 years from now) | |
US9765028 | MYLAN IRELAND LTD | Crystalline freebase forms of a biphenyl compound |
Jul, 2030
(5 years from now) | |
US10550081 | MYLAN IRELAND LTD | Crystalline freebase forms of a biphenyl compound |
Jul, 2030
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11008289 | MYLAN IRELAND LTD | Crystalline freebase forms of a biphenyl compound |
Jul, 2030
(5 years from now) | |
US11691948 | MYLAN IRELAND LTD | Crystalline freebase forms of a biphenyl compound |
Jul, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Nov 09, 2023 |
Drugs and Companies using REVEFENACIN ingredient
NCE-1 date: 09 November, 2022
Market Authorisation Date: 09 November, 2018
Treatment: For the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8983594 | TEVA BRANDED PHARM | Electronic control of drug delivery system |
Nov, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosage Form(NDF) | Jan 17, 2016 |
Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 17 January, 2013
Treatment: Method for treating acute migraine in adults, with or without aura, comprising iontophoretic transdermal delivery of sumatriptan or a salt thereof
Dosage: SYSTEM
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8741920 | HOFFMANN LA ROCHE | Process for the manufacture of pharmaceutically active compounds |
Jul, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Aug 17, 2016 |
Orphan Drug Exclusivity(ODE) | Aug 17, 2018 |
Orphan Drug Exclusivity(ODE-13) | Aug 17, 2018 |
M(M-184) | Aug 31, 2019 |
New Indication(I-757) | Nov 06, 2020 |
Orphan Drug Exclusivity(ODE-158) | Nov 06, 2024 |
Drugs and Companies using VEMURAFENIB ingredient
NCE-1 date: 18 August, 2015
Market Authorisation Date: 17 August, 2011
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10376538 | LNHC | Topical gels and methods of using the same |
Aug, 2030
(5 years from now) | |
US9737561 | LNHC | Topical gels and methods of using the same |
Aug, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jan 05, 2029 |
Drugs and Companies using BERDAZIMER SODIUM ingredient
NCE-1 date: 06 January, 2028
Market Authorisation Date: 05 January, 2024
Treatment: Method of treating skin ailment with nitric oxide releasing macromolecules and hydrophilic gel
Dosage: GEL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10239846 | BRISTOL | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
Nov, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-860) | May 27, 2024 |
New Chemical Entity Exclusivity(NCE) | Mar 25, 2025 |
M(M-309) | Aug 30, 2027 |
Drugs and Companies using OZANIMOD HYDROCHLORIDE ingredient
NCE-1 date: 25 March, 2024
Market Authorisation Date: 25 March, 2020
Treatment: Treatment of moderately to severely active ulcerative colitis (uc) in adults
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8829005 | HARROW EYE | Ophthalmic formulations of cetirizine and methods of use |
Mar, 2030
(5 years from now) | |
US9993471 | HARROW EYE | Ophthalmic formulations of cetirizine and methods of use |
Mar, 2030
(5 years from now) | |
US9750684 | HARROW EYE | Ophthalmic formulations of cetirizine and methods of use |
Mar, 2030
(5 years from now) | |
US8829005 (Pediatric) | HARROW EYE | Ophthalmic formulations of cetirizine and methods of use |
Sep, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosage Form(NDF) | May 30, 2020 |
Pediatric Exclusivity(PED) | Nov 30, 2020 |
Drugs and Companies using CETIRIZINE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 May, 2017
Treatment: Treatment of ocular itching associated with allergic conjunctivitis
Dosage: SOLUTION/DROPS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10946101 | JOURNEY | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
Oct, 2030
(5 years from now) | |
US8945516 | JOURNEY | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
Oct, 2030
(5 years from now) | |
US10213512 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(5 years from now) | |
US12138311 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(5 years from now) | |
US8992896 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(5 years from now) | |
US9675700 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(5 years from now) | |
US8865139 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(5 years from now) | |
US10322186 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(5 years from now) | |
US10265404 | JOURNEY | Compositions, gels and foams with rheology modulators and uses thereof |
Oct, 2030
(5 years from now) |
Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient
Market Authorisation Date: 28 May, 2020
Treatment: Treatment of inflammatory lesions of rosacea
Dosage: AEROSOL, FOAM
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8679544 | ZYLA | Formulation of diclofenac |
Apr, 2030
(5 years from now) | |
US9180096 | ZYLA | Formulation of diclofenac |
Apr, 2030
(5 years from now) | |
US9173854 | ZYLA | Formulation of diclofenac |
Apr, 2030
(5 years from now) | |
US9017721 | ZYLA | Formulation of diclofenac |
Apr, 2030
(5 years from now) | |
US9186328 | ZYLA | Formulation of diclofenac |
Apr, 2030
(5 years from now) | |
US9180095 | ZYLA | Formulation of diclofenac |
Apr, 2030
(5 years from now) | |
US8999387 | ZYLA | Formulation of diclofenac |
Apr, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Oct 18, 2016 |
New Indication(I-692) | Aug 22, 2017 |
Drugs and Companies using DICLOFENAC ingredient
Market Authorisation Date: 18 October, 2013
Treatment: Treatment of pain
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8470361 | OREXO US INC | Non-abusable pharmaceutical composition comprising opioids |
May, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-713) | Aug 10, 2018 |
Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 04 October, 2016
Treatment: Sublingual administration of a pharmaceutical composition comprising buprenorphine and naloxone
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9095577 | AQUESTIVE | Stabilized amine-containing actives in oral film compositions |
Jul, 2030
(5 years from now) |
Drugs and Companies using ONDANSETRON ingredient
Market Authorisation Date: 02 July, 2010
Treatment: NA
Dosage: FILM
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11850245 | BAUSCH | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts |
Apr, 2030
(5 years from now) | |
US11202752 | BAUSCH | Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy |
Apr, 2030
(5 years from now) | |
US10918635 | BAUSCH | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts |
Apr, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Mar 25, 2013 |
New Indication(I-636) | Mar 24, 2014 |
New Strength(NS) | Jul 15, 2014 |
Drugs and Companies using IMIQUIMOD ingredient
Market Authorisation Date: 15 July, 2011
Treatment: Treatment of genital warts; Treatment of perianal warts
Dosage: CREAM
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9492449 | GILEAD SCIENCES INC | Therapies for hematologic malignancies |
Mar, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jul 23, 2019 |
Orphan Drug Exclusivity(ODE) | Jul 23, 2021 |
Orphan Drug Exclusivity(ODE-70) | Jul 23, 2021 |
Orphan Drug Exclusivity(ODE-71) | Jul 23, 2021 |
Drugs and Companies using IDELALISIB ingredient
NCE-1 date: 23 July, 2018
Market Authorisation Date: 23 July, 2014
Treatment: In combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (cll)
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8039479 | NOVARTIS | Compounds and compositions as protein kinase inhibitors |
Jun, 2030
(5 years from now) | |
US8039474 | NOVARTIS | 2,3,4,9-tetrahydro-1H-carbazole derivatives as CRTH2 receptor antagonists |
Jun, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Apr 29, 2019 |
M(M-199) | May 26, 2020 |
Orphan Drug Exclusivity(ODE-66) | Apr 29, 2021 |
Orphan Drug Exclusivity(ODE) | May 26, 2024 |
ODE*(ODE*) | May 26, 2024 |
Orphan Drug Exclusivity(ODE-145) | May 26, 2024 |
Drugs and Companies using CERITINIB ingredient
NCE-1 date: 29 April, 2018
Market Authorisation Date: 18 March, 2019
Treatment: NA
Dosage: CAPSULE
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
US8420081 | ABBVIE INC. | Antibody formulations and methods of making same |
Jan, 2030
(4 years from now) |
Ingredients: ADALIMUMAB
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
US8053236 | AMGEN INC. | Feed media |
Jan, 2030
(4 years from now) | |
US9228168 | AMGEN INC. | Feed media |
Jan, 2030
(4 years from now) | |
US9320816 | AMGEN INC. | Methods of treating cell culture media for use in a bioreactor |
Nov, 2030
(5 years from now) |
Ingredients: DENOSUMAB
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
US9696307 | BIOGEN INC. | Methods for the detection of JC polyoma virus |
Feb, 2030
(4 years from now) | |
US9005926 | BIOGEN INC. | Methods of preventing and removing trisulfide bonds |
Oct, 2030
(5 years from now) | |
US9212379 | BIOGEN INC. | Nutrient monitoring and feedback control for increased bioproduct production |
Nov, 2030
(5 years from now) |
Ingredients: NATALIZUMAB
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
US9856287 | AMGEN INC. | Refolding proteins using a chemically controlled redox state |
Jun, 2030
(5 years from now) |
Ingredients: PEGFILGRASTIM
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
US9714293 | GENENTECH, INC. | Production of proteins in glutamine-free cell culture media |
Aug, 2030
(5 years from now) | |
US10982003 | GENENTECH, INC. | Production of proteins in glutamine-free cell culture media |
Aug, 2030
(5 years from now) | |
US11377678 | GENENTECH, INC. | Method for the production of a glycosylated immunoglobulin |
Oct, 2030
(5 years from now) | |
US11136610 | GENENTECH, INC. | Method for the production of a glycosylated immunoglobulin |
Oct, 2030
(5 years from now) | |
US11021728 | GENENTECH, INC. | Method for the production of a glycosylated immunoglobulin |
Oct, 2030
(5 years from now) | |
US10501769 | GENENTECH, INC. | Method for the production of a glycosylated immunoglobulin |
Oct, 2030
(5 years from now) |
Ingredients: TOCILIZUMAB